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Assessment of coding region 
variants in Kuwaiti population: 
implications for medical genetics 
and population genomics
Sumi Elsa John1, Dinu Antony1,2, Muthukrishnan Eaaswarkhanth  1, Prashantha Hebbar1, 
Arshad Mohamed Channanath1, Daisy Thomas1, Sriraman Devarajan1, Jaakko Tuomilehto1, 
Fahd Al-Mulla1, Osama Alsmadi1,3 & Thangavel Alphonse Thanaraj1
Consanguineous populations of the Arabian Peninsula have been underrepresented in global efforts 
that catalogue human exome variability. We sequenced 291 whole exomes of unrelated, healthy 
native Arab individuals from Kuwait to a median coverage of 45X and characterised 170,508 single-
nucleotide variants (SNVs), of which 21.7% were ‘personal’. Up to 12% of the SNVs were novel and 
36% were population-specific. Half of the SNVs were rare and 54% were missense variants. The study 
complemented the Greater Middle East Variome by way of reporting many additional Arabian exome 
variants. The study corroborated Kuwaiti population genetic substructures previously derived using 
genome-wide genotype data and illustrated the genetic relatedness among Kuwaiti population 
subgroups, Middle Eastern, European and Ashkenazi Jewish populations. The study mapped 112 rare 
and frequent functional variants relating to pharmacogenomics and disorders (recessive and common) 
to the phenotypic characteristics of Arab population. Comparative allele frequency data and carrier 
distributions of known Arab mutations for 23 disorders seen among Arabs, of putative OMIM-listed 
causal mutations for 12 disorders observed among Arabs but not yet characterized for genetic basis 
in Arabs, and of 17 additional putative mutations for disorders characterized for genetic basis in Arab 
populations are presented for testing in future Arab studies.
Characterising the patterns of genetic variation within and among human populations is crucial to under-
stand human evolutionary history and the genetic basis of disorders1. Many global genome-wide genotyping 
and whole-genome sequencing studies (such as the Human Genome Diversity Project1,2, the 1000 Genomes 
Project (1KGP)3,4 and the UK10K project5) have been undertaken to catalogue genetic variation. Coding exonic 
regions, though estimated to encompass only approximately 1–2% of the genome, harbour the most functional 
variation and contain almost 85% of the known disease-causing pathogenic variants6,7; therefore, several global 
whole-exome sequencing studies have also been undertaken8–10. Such large-scale global projects have revealed 
that human populations harbour a large amount of rare variations which exhibit little homology between diverged 
populations3,9–17, Mendelian and rare genetic disorders are often associated with rare coding variants. Likewise, 
common markers associated with complex disorders too can vary in frequency across populations18. Considering 
that population-specific differences in allele frequencies are of clinical importance, it is fundamental to catalogue 
them in diverse ethnic populations19.
The Arabian Peninsula holds a strategic place in the early human migration routes out of Africa20–22. The 
Peninsula was instrumental in shaping the genetic map of current global populations because the first Eurasian 
populations were established here23. The ancestry of indigenous Arabs can largely be traced back to ancient lin-
eages of the Arabian Peninsula23,24. The Arab population is heterogeneous but well-structured3,24–26. For exam-
ple, the Kuwaiti population comprises three genetic subgroups, namely KWP (largely of West Asian ancestry 
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representing Persians with European admixture), KWS (city-dwelling Saudi Arabian tribe ancestry) and KWB 
(tent-dwelling nomadic Bedouins characterised by the presence of 17% African ancestry)24. Further, the Qatari 
population also comprises similar subgroups with the third group displaying a much higher African ancestry25. 
The Greater Middle Eastern Variome study26 detected several ancient founder populations and continental & 
sub-regional admixture in the extended region of Greater Middle East (comprising the Gulf region, North Africa 
and Central Asia); the study further stated that the ancestral Arab population from Arabian Peninsula could be 
observed in nearly all of the GME regions possibly as a result of the Arab conquests in the seventh century.
Consanguinity in the Arab region has made the population vulnerable to a plague of recessive genetic dis-
orders. An increased burden of runs of homozygosity has been observed in populations from Kuwait24 and the 
extended region of Greater Middle East26. An overwhelming proportion (63%) of the disorders documented in 
the Catalogue for Transmission Genetics in Arabs (CTGA)27 follows a recessive mode of inheritance28. Studying 
consanguineous populations lead to identifying causal mutations for Mendelian disorders29,30 and rare familial 
(monogenic) forms of common complex disorders31. These studies also paved the way to evaluate the role of con-
sanguinity and environmental factors in complex lifestyle disorders, such as obesity and type 2 diabetes, cases of 
which are rapidly increasing in the Arabian Peninsula32,33. Thus, studying consanguineous populations is impor-
tant to human medical genetics research26,34,35.
Despite consanguinity, diversity and admixture in its populations, the region is poorly represented in global 
genomic surveys. Even larger databases, such as the Exome Aggregation Consortium (ExAC)8 and the Genome 
Aggregation Database (gnomAD)8, are deficient in representing Middle Eastern populations. Although the 
Greater Middle East (GME) Variome project26 provides whole exome data of 1,111 individuals from six GME 
regions, the region of Arabian Peninsula is represented by only 214 samples and the sub-region of Kuwait by only 
45 samples.
In our previous studies, we sequenced and analysed thirteen exomes from the KWS group36 and representa-
tive whole genomes from each of the three subgroups of the Kuwaiti population36–38. In this study, we extended 
the study by sequencing whole exomes of 291 native Kuwaiti Arab individuals representing the three population 
subgroups. We further analysed the data to infer the extent of exome variability in the Kuwaiti population and to 
delineate its impact on population substructures of Kuwait and medical genetics of the region.
Results
Exome variants discovered in the Kuwaiti population. The 291 exomes were sequenced to a median 
coverage of 45X, with an average of 80% of the target base pairs having at least 15X coverage. ‘Missingness’ rate 
(referring to the percent of samples where information was missing) of 1.8% was obtained leading to genotyp-
ing call rate of 98.2%. Totally, 173,849 (including 2,626 non-autosomal) variants were identified (Table 1 and 
Supplementary Table S1), 12.16% of which were novel. The call set included 170,508 single-nucleotide variants 
(SNVs) and 3,341 insertions and deletions (indels). 11.85% of the SNVs and 28% of the indels were novel. The 
All variants Kuwaiti ‘population-specific’ variants@
Kuwaiti ‘Population-specific’ variants seen 
in ≥2 individuals from the study cohort
Number of 
variants
Average number of 
variants per individual
Number of 
variants
Average number of 
variants per individual
Number of 
variants
Average number of 
variants per individual
Total variants (% novel) 173849 (12.16) 14767 57691 (36.63) 365 9870 (34.73) 189
SNVs (% novel) 170508 (11.85) 14557 55644 (36.3) 331 9429 (35.03) 168
Indels (% novel) 3341 (28.07) 210 2047 (45.72) 34 441 (28.34) 21
Ti:Tv 3.22 3.374 2.7 2.44 2.7 2.37
‘Personal’ SNVs# 37044 129 37044 129 0 0
Rare SNVs (excluding 
‘personal’ variants) 86446 908 17579 109 8408 74
Low-frequency SNVs 21277 1553 883 27 883 27
Common SNVs 25741 11969 138 67 138 67
Missense SNVs$ 91204 9187 33504 184 5559 87
Synonymous SNVs$ 70955 10385 19159 126 3377 70
Stop gain SNVs$ 1425 65 721 3 113 1
Stop loss SNVs$ 95 9 22 0 4 0
LoF& SNVs$ 1645 73 843 4.5 131 2
Table 1. Statistics of variants observed in Kuwaiti exomes. Ti:Tv, transition/transversion ratio. @Variants from 
our cohort that were not seen in 1KGP were termed as ‘Kuwaiti population-specific’ variants. #Personal SNVs 
are those that are observed only in a single exome from the study cohort and not seen in the data sets of 1KGP 
or GME. These are indeed “private mutations” and remain so until the mutations are observed in further 
exomes/genomes sequenced in future studies. &Loss-of-function (LoF) variants represent the sum total of 
stop gain, stop loss, frameshift and splicing variants. LoF variants are expected to correlate with complete loss 
of function of the affected transcripts, including stop codon-introducing (nonsense) or splice site-disrupting 
single-nucleotide variants (SNVs), insertion/deletion (indel) variants predicted to disrupt a transcript’s reading 
frame or larger deletions removing either the first exon or >50% of the protein-coding sequence of the affected 
transcript. $These were calculated using all the identified SNVs including the personal variants.
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observed aggregate transition/transversion (Ti:Tv) ratio of 3.22 was within the acceptable range for whole-exome 
sequencing variants39,40. A heterozygous to homozygous variant genotype ratio of 0.63 was obtained indicating 
that the population skews towards homozygosity with its inbreeding nature.
Validation of SNP calls. The validity of the SNP calls was confirmed by utilizing an in-house genome-wide 
genotype data set on 269 (of the sequenced 291) samples derived using the Illumina HumanOmniExpress 
BeadChip (Illumina Inc, USA). In an average, 13,175 variants could be compared per sample. The concordance 
rate of the SNP calls between the exome sequencing data and genome-wide genotype data was >99.7% (see 
Supplementary Table S2). The observed concordance rate in our study is on par with those reported in literature: 
Kenna et al.40 reported a genotype concordance rate of 98.9% on comparing the accuracy of genotypes inferred 
using Illumina high throughput sequencing platforms with genotypes ascertained using Illumina BeadChips. The 
disagreements in the SNP calls were seen more often with heterozygous SNPs than with homozygous SNPs. As is 
the practice41, we choose not to remove the inconsistent calls.
Principal component analysis of variants in the merged set of exome variants from Kuwait and 
global populations. The scatter plot of the first two principal components of the merged data set of exome 
variants from Kuwait, 1KGP global populations, and Qatar is presented in Fig. 1. The plot affirmed the heteroge-
neity of the Kuwaiti Arab population as comprising three substructures24 and inferred the regional affinity.
Classifications of observed SNVs. 50.7% of the identified SNVs were ‘rare’, 12.5% were ‘low-frequency’ 
and 15.1% were ‘common’. Up to 21.7% of the SNVs were ‘personal’ (found in only one Kuwaiti exome and not 
seen in the data sets of 1KGP Phase 3 and GME). Alternate allele was the major allele in 4.2% of the identified 
SNVs; 0.22% of the SNVs were fixed for the alternate allele, having a non-reference frequency of 100%. Among 
the identified SNVs, 53.5% were missense, 41.61% were synonymous and approximately 1% were loss-of-function 
(LoF). 55,644 of the identified SNVs were ‘population-specific’, 60% of which were missense; 9,429 of these 55,644 
population-specific variants were polymorphic (seen in ≥2 exomes from the study cohort and not seen in 1KGP), 
most of which were ‘rare’ (8408 out of 9429); of the remaining 46,215 variants, 37,044 were ‘personal’ and 9171 
were seen in one exome from the study cohort and were also seen in GME data set. On average, 14,557 SNVs 
and 210 indels were seen in every Kuwaiti individual. The average number of ‘personal variants’ per individual 
was 129. Population-specific missense variants per individual were more than synonymous changes (184 versus 
126). The average number of LoF variants per Kuwaiti individual was 73, of which 4.5 were specific to the Kuwaiti 
population.
Homozygous LOF variants and “inactivated genes”. We had observed 1645 putative LoF SNVs 
(Table 1) in Kuwaiti exomes from 291 healthy individuals of Arab ethnicity. 186 of these 1645 LoF SNVs were 
homozygous and they were harbored in 179 genes (See Supplementary Table S3). Of the 186 homozygous LoF 
SNVs, 27 were with MAF <1% and another 9 were with MAF (≥1% and <2%). Sulem et al.42, by way of per-
forming whole-genome sequencing of 2,636 Icelanders and chip-imputing a further 101,584 Icelanders, had 
identified a set of rare (MAF <2.0%) homozygous LoF variants in 1,171 genes. In a similar manner, the Exome 
Aggregation Consortium (ExAC) data set of 60,706 sequenced individuals identified 2,068 genes that were inac-
tivated8; The GME26 consortium, by way of analyzing 354 exomes of healthy individuals, identified 301 genes 
with rare homozygous LoF variants of which 50 genes overlapped the Icelandic gene list and 94 overlapped the 
Figure 1. Scatter plot of the first two principal components of the merged data set of exome variants from the 
three Kuwaiti substructures and from regional (Qatar) and 1KGP global populations.
www.nature.com/scientificreports/
4SCiENTifiC REPORTS |         (2018) 8:16583  | DOI:10.1038/s41598-018-34815-8
ExAC gene list of inactivated genes. Upon comparing the homozygous LoF variants from the Kuwaiti exomes 
with the above-mentioned data sets of inactivated genes, we found 23 genes (PNPLA1, ULBP3, OR8K3, RAD52, 
APOBEC1, PDIA2, WDR87, SIGLEC1, COL9A2, OTOF, SULTIC3, COQ2, MROH2B, FAM81B, UNC93A, 
DNAH11, PXDNL, OR4D10, SLC22A24, RNASE9, C17orf77, CARD14 and SLC5A4) in common with Icelandic 
data set, 3 genes (EML1, WWTR1 and PPFIA1) in common with ExAC data set and six genes (COL9A2, SLC5A9, 
FAM81B, GGT6, EFCAB13 and SLC5A4) in common with GME data set. Upon considering only those LoFs with 
<2% MAF in Kuwaiti exomes, the number of genes in common with Icelandic data got reduced to 8 - PNPLA1 
(MAF_KWT of the LoF: 1.03), ULBP3 (0.52%), OR8K3 (1.5%), RAD52 (1.3%), APOBEC1 (0.34%), PDIA2 
(1.3%), WDR87 (0.34%) and SIGLEC1 (0.34%)); upon considering only the rare (MAF <1%) homozygous LoF 
variants in Kuwaiti exomes, only one gene (EML1 (0.69%)) was seen in common with ExAC data set; and none 
with GME data set. GME work reported more genes as common with the Icelandic/ExAC data sets as they also 
considered indels along with SNVs to derive the list of LOFs while we considered only the SNVs.
Comparison with Greater Middle East (GME) Variome data. Results of comparing the variants 
observed in our study with those reported in GME populations26 are presented in Table 2. Up to 64% of the 
SNVs identified in our study were seen common with GME – the remaining 36% of variants not seen in GME are 
expected to enlarge the variome of the GME region. GME provided supporting evidence to designate up to 25% 
of Kuwaiti population-specific singleton mutations (seen in only one exome from the study cohort) as genuine 
SNVs. Up to as high as 58% of the population-specific polymorphic variants observed in Kuwaiti exomes were 
also seen in GME variome.
Extent of variability in Kuwaiti exomes. In each of the categories of ‘all’, ‘known’, ‘novel’ and ‘Kuwaiti 
population-specific’ variants, the observed number of variants increased linearly with increasing number of 
sequenced exomes and did not reach a plateau (Fig. 2). A similar trend was observed when the three subgroups 
were examined individually (Supplementary Fig. S1). However, when the population-specific variants were 
divided into ‘personal’ and ‘population-specific polymorphic’ variants, population-specific variants shared by 
more than one individual reached a plateau.
Variants significantly differentiating the three population subgroups of Kuwait. Results of 
pFst likelihood ratio tests for allele frequency differences between the three subgroups based on 142,626 auto-
somal variants are presented in Supplementary Fig. S2. Three variants significantly distinguished KWP from 
KWB: rs2289043_A > G (UNC5C) (pFst = 3.28 × 10−6), mostly prevalent in admixed Americans (75%) and 
Europeans (71%); rs3739310_T > G (KIAA1456) (pFst = 4.40 × 10−5), frequently found in East Asians (78%) and 
Europeans (77%); and rs764374986_G > A (AKAP12) (pFst = 5.21 × 10−5), a rare variant occurring mostly in 
Africans (0.01%) from gnomAD data set (the variant is absent in 1kGP data set). Three variants significantly 
distinguished KWS from KWB:rs1150360_A > G (FAM76B) (pFst = 3.89 × 10−5), frequent in Africans (93%); 
rs138408584_G > C (PHRF1) (pFst = 6.97 × 10−5), rare in Europeans (~1%); and rs1043730_G > T (TRAF3IP2) 
(pFst = 9.57 × 10−5), present at 99% frequency in Africans and East Asians. Two variants significantly distin-
guished KWP from KWS: rs35840170_C > T (FBN3) (pFst = 7.63 × 10−5), present at ~20% frequency in East 
Asians and admixed Americans; and rs7956133_G > T (FAM216A) (pFst = 9.51 × 10−5) present at a frequency 
of 15% in Africans.
SAFD variants with significant allele frequency differences between the Kuwaiti and 1KGP 
global populations; and analysis of their population-wide occurrence. Examination of the SNVs 
seen in common between Kuwaiti exomes and 1KGP phase 3 exome data for significant allele frequency dif-
ferences led to identifying 6,186 SAFD variants. Functional characterization of these variants is presented in 
Supplementary Table S4. Of these 6,186 SAFD variants, 2,960 were missense, 2,913 were synonymous, 20 were 
stop-gain and 26 were LoF. Extent of LoF variants among the SAFD SNVs was only 0.4% while it was 1.7% among 
the ‘all’ SNVs. Population-wide occurrence of the identified SAFD variants was investigated to determine the 
pairing occurrence of Kuwaiti population subgroups in the context of maximum allele frequency (Supplementary 
Fig. S3 and Fig. 3). (a) Analysis of the 5,140 SAFD variants, derived using gnomAD populations: The number 
of variants showing maximum allele frequency in KWS, KWP and KWB subgroups were 2885, 543 and 1712, 
respectively. In KWS, 38% of the 2885 variants showed maximum allele frequency in Ashkenazi Jews and 19% in 
Africans. In KWP, 35% had maximum allele frequency in Ashkenazi Jews and 33% in South Asians. In KWB, 61% 
variants showed maximum allele frequency in Africans. (b) Analysis of 6186 SAFD variants, derived using 1KGP 
populations: Coupling observed with South Asians and Africans was confirmed. KWB paired with Africans 
in 21% of 1,056 variants; KWP and KWS paired with South Asians in 31% of 1355 and 17% of 3775 variants, 
SNV Category
Total observed in 
Kuwaiti Arabs
Present in GME 
variome
Present only in the “Arabian 
Peninsula” subregion of GME
All 170508 109058 (64%) 4351
All:Personal 37044 0 (0%) 0
Kuwaiti “Population-specific” 55644 14660 (26.3%) 2393
Kuwaiti “Population-specific polymorphic” variants 
seen in ≥2 individuals from the study cohort 9429 5474 (58%) 793
Table 2. Comparing the Kuwaiti Arab whole-exome variants with Greater Middle East (GME) whole-exome 
Variome.
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respectively. Furthermore, coupling with Europeans, which was not seen in the analysis using gnomAD popula-
tions, was observed in 53% of KWS variants, 52% of KWP variants and 41% of KWB variants.
Validation of the genetic relatedness implied by analysis for population-wide occurrence of 
SAFD variants. In order to further explore the observed coupling in maximum allele frequency between 
Kuwaitis and other populations (including the Ashkenazi Jews), Kuwaiti exome data was merged with the data 
sets from Ashkenazi Jews43, Qatar44 and 1KGP phase 3. Upon applying quality control steps and LD-pruning the 
combined data set of coding-region variants, a total of 896 variants from 3,336 individuals was obtained. Genetic 
differentiation of Kuwaiti subpopulation groups in terms of regional and continental populations was assessed 
by way of calculating mean pairwise FST (Supplementary Fig. S4, Supplementary Table S5). Lowest degree of 
differentiation was observed between Kuwaiti subpopulation groups and Qataris (KWB FST = 0.0005, KWP 
FST = 0.0027, KWS FST = 0.0023) followed with Ashkenazi Jews (KWB FST = 0.0103, KWP FST = 0.0071, KWS 
FST = 0.0104) and Europeans (KWB FST = 0.0143, KWP FST = 0.0093, KWS FST = 0.0155). Scatter plots resulting 
from principal component analysis (PCA) of the merged data set are presented in Figs 4 and 5. Consistent with 
the FST analysis, the Kuwaiti population were seen dispersed over the Qataris, Ashkenazi Jewish and Europeans 
(Fig. 4). A clear dispersal of these populations was seen in the three-dimensional PCA plot (Fig. 5 and the inter-
active three-dimensional plot available at http://dgr.dasmaninstitute.org/exome_pca/).
‘Rare and deleterious’ variants and their clinical significance. The analysis pipeline that examined 
the Kuwaiti exomes for deleterious variants which are rare in both 1KGP and ExAC data sets yielded a list of 46 
variants (41 unique disorders of which 20 were reported in CAGS database) – comprising 35 pathogenic (for rare 
disorders), 1 drug response, 10 risk factors (1 corresponding to a rare but multifactorial disorder and the remain-
ing 9 to complex and common disorders) (Table 3). Of these 46 variants, 43 variants remained rare in Kuwaiti 
exomes; and three variants reached an MAF value characterizing low-frequency variants (rs1800553/ABCA4/
Risk-Factor:2.41%, rs61742245/VKORC1/Drug-response:1.04%, rs11909217/LIPI/Risk-Factor:1.72%). 
Pathogenic variants: The 35 pathogenic variants mapped to 32 genes and to 32 unique single-gene disorders; 28 
of the 35 variants follow autosomal recessive (AR) and the remaining follow autosomal dominant (AD) mode 
of inheritance. In 16 instances of these 35 pathogenic variants, the disorders were observed in Arab population 
(as annotated in CAGS database27). Drug response variant: the VKORC1 variant was associated with warfarin 
resistance in AD mode. Risk factor variants: The 10 risk factor variants mapped to 9 genes and to susceptibility 
to 8 unique disorders. The inheritance patterns were seen to be mostly autosomal dominant (in three instances, 
can be AR along with AD). In instances of 4 of the 10 risk factor variants, the disorders were observed in Arab 
population as per CAGS database.
Pathogenic variants and high MAF in Kuwaiti exomes. Five of the identified “rare & deleterious” variants that 
were annotated “pathogenic” for clinical significance in ClinVar were seen to possess risk allele frequencies of 
≥1% in Kuwaiti exomes as opposed to <1% in 1KGP populations. ClinVar defines “pathogenic” variants as those 
that are interpreted for Mendelian disorders; or as those that have low penetrance. It is also possible that a variant 
in ClinVar can have an erroneous or conflicting classification. Cassa et al.45 examined 81,432 “pathogenic” vari-
ants from HGMD7 in a data set of whole-genome sequences of 1.092 individuals from 1KGP project and found 
Figure 2. Distribution of total number of single-nucleotide variants (SNVs) upon step-wise addition of exomes. 
The red line represents the number of all variants found as the number of sequenced exomes increased. The 
green line represents the number of known variants among all variants found. The orange line represents the 
number of novel variants among all variants found. The blue line represents the number of population-specific 
variants among all variants found. Population-specific ‘personal’ variants observed in only one Kuwaiti exome 
and not seen in either 1KGP or GME are represented by the dotted line; population-specific ‘polymorphic’ 
variants observed in more than one Kuwaiti exome are represented by the dashed line.
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that 4.62% of the tested variants to possess an MAF of ≥1% and 3.5% of the tested variants to possess an MAF 
of ≥5%; they concluded that many of these variants are probably erroneous findings or have lower penetrance 
than previously expected. It is also possible that such high frequency pathogenic variants are indeed of the type 
“increased susceptibility” and not of the type “causal”; it is also possible that the disorders with such high MAF 
“pathogenic” variants are not really “rare” but are either “common” or “more prevalent in the study population”; 
that it is also possible that the frequent variants have evidence to cause a disease when inherited in compound het-
erozygous state and have insufficient evidence to lead to a disease in homozygotes. The five “pathogenic” variants 
that were seen in Kuwaiti exomes with an MAF of ≥1% are as follows:
(a) Four variants retained as pathogenic for rare disorders: (i) rs79204362 (MAF_KWT:1.03% and MAF_1KGP: 
0.42%) associated with Early onset of Glaucoma: ClinVar annotated this variant as Pathogenic based on evidence 
Figure 3. The occurrence pattern of pairing Kuwaiti populations with (a) the gnomAD or (b) the 1KGP global 
populations as populations with maximum allele frequency. X-axis: percentage of pairing occurrence of Kuwaiti 
populations and gnomAD (A) or 1KGP (B) global populations as populations with maximum allele frequency, 
Y-axis: Kuwaiti populations (KWT-All Kuwaitis; KWB-Bedouins; KWP-Persians; KWS-Saudi Arabian tribe). 
gnomAD global populations: AFR, Africans/African Americans; AMR, admixed Americans; ASJ, Ashkenazi 
Jewish; EAS, East Asians; FIN, Finnish; NFE, Non-Finnish Europeans; OTH, Other population not assigned; 
SAS, South Asians. 1KGP global populations: AFR, African; AMR, Admixed American; EAS, East Asian; 
EUR, European; SAS South Asian. (c) Considers only the variants with minor allele frequency (MAF) of >5% 
(n = 3887) and pairing with 1KGP global populations.
Figure 4. Two-dimensional principal component analysis (PCA) plots showing the dispersal of Kuwaitis over 
the Qataris, Ashkenazi Jewish and Europeans.
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from literature studies and as of uncertain significance based on clinical testing. The disorder was supposed to 
be rare (1 in 10,000) in European-based populations and of higher frequency in Middle East 51–100 per 100,000 
(i.e. 5 in 10,000); CTGA reported a high incidence rate of 1 in 2,500 in Saudi Arabian population. Thus, the 
MAF that is seen marginally higher at 1.03% was acceptable. (ii) rs61732874_C > A (MAF_KWT:1.55% and 
MAF_1KGP: 0.18%) associated with Familial Mediterranean fever (FMF): ClinVar annotated this as Pathogenic/
likely-pathogenic based both on literature evidence and clinical testing. FMF is a rare disorder in European pop-
ulation; however, it is no longer a rare disorder in certain populations such as Japan (see Table 7). CAGS also 
listed the incidence as 51–100 per 100,000 in Arab population; CAGS further mentioned that estimates of the 
incidence of FMF in specific eastern Mediterranean populations ranged from 1 in 2000 to 1 in 100, depending on 
the population studied. Thus, the MAF that is seen at 1.55% was acceptable. (iii) rs61757294 (MAF_KWT:15.19% 
and MAF_1KGP:5.3%) associated with Corticosterone Methyloxidase Type II Deficiency, a rare genetic disorder: 
ClinVar annotated this variant as pathogenic based on evidence from literature publication and benign based 
on clinical testing records. The variant was found in patients of Iranian Jewish ancestry. This had DR mode of 
inheritance – both this variant and another one rs289316 need to be homozygous; thus, the observed high MAF 
was acceptable; in fact, the variant was a common variant in 1KGP as well. (iv) rs12021720 (MAF_KWT:13.47% 
and MAF_1KGP:10.9%) associated with Maple syrup urine disease, intermediate, type II (a rare genetic disorder): 
ClinVar annotated this variant as pathogenic based on literature evidence and as benign with clinical testing as 
source of annotation. Though the incidence rate world-wide is 1 in 185,000, CAGS reported an incidence rate of 
2 in 10,000 in Bahrain - still the higher MAF is not justified. This mutation was seen in one of the three patients 
from the study46 and the patient was a compound heterozygote for a C to G transversion at nucleotide 309 in exon 
4 [rs121965001] and a G to A transition at nucleotide 1165 in exon 9 [rs12021720], causing an Ile-to-Met substi-
tution at amino acid 37 and a Gly-to-Ser substitution at amino acid 323, respectively. Thus, the high frequency of 
MAF at one of the two variants of the compound heterozygotes was acceptable for pathogenic variant; in fact, the 
variant was a common variant in 1KGP as well. (b) One variant retained as pathogenic for rare disorder but with a 
suggestion that they can be “likely benign”: rs61751507 (MAF_KWT:7.47% and MAF_1KGP:2.7%) associated with 
Carboxypeptidase N deficiency, which is possibly a complex disorder. ClinVar annotated this variant as patho-
genic with evidence from literature publication and benign based on information clinical testing. The study47 
found this pathogenic variant in just one patient and hence it may be considered as of insufficient evidence. Hence 
this variant can be considered as “Likely Benign”.
Missense variants rare within global populations but common within Kuwaiti population. 170 
SNVs were identified as rare in global populations but common in Kuwaiti exomes; 85 of these were missense 
variants (Supplementary Table S6). The 85 variants were of two categories: (a) A set of 20 variants harboured in 
genes annotated for disorders in OMIM: However, these 20 variants were not of any pathogenic value as ClinVar 
annotated these variants as either ‘benign’ or ‘conflicting interpretation’. Not surprisingly, the REVEL scores in 
these instances (except in 2 instances – GLDC variant at around 0.8; and the DPYD variant at 0.4) were seen 
low at ≤0.3. (b) A set of 65 variants harboured in genes NOT annotated for any disorder in OMIM: Association 
with phenotypes was seen with only one of these 85 variants; the TTC38 variant rs117135869 (REVEL = 0.621; 
MAF_KWT: 5.0%; MAF_1KGP: 0.58%) has been recently identified as a novel metabolic quantitative trait loci 
Figure 5. Three-dimensional principal component analysis (PCA) plots showing the dispersal of Kuwaitis over 
the Qataris, Ashkenazi Jewish and Europeans. The interactive three-dimensional plot is available at http://dgr.
dasmaninstitute.org/exome_pca/).
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dbSNP; Ref/risk; gene
Inheritance mode (AD:autosomal 
dominant; AR:autosomal recessive; 
MF:multifactorial)
Disorder (PMIM); No of OMIM-listed genes for 
the disorder; annotation pertaining to whether 
the disorder is rare or common$
RAFs: KWT/1KGP/GME; Ratios of 
RAFs: KWT-1KGP/KWT-GME
Carrier status in 
Kuwaiti exomes 
(rr/rR/RR)
Disorder seen in 
CAGS populations 
(YES/NO)?
A. PATHOGENIC and rare disorders CAUSAL VARIANTS (n = 34)
rs137853054-G/A; PARK2 AR Parkinson disease, juvenile, type 2 (PMIM:600116)92; Single gene; Rare disorder. 0.0034/0.0002/0.0025; 17.0000/1.3503 0/2/288 Yes
rs34424986-G/A; PARK2 AR. This and the above both participate in compound heterozygosity
Parkinson disease, juvenile, type 2. (PMIM:600116). 
Single gene; Rare disorder. 0.0034/0.0004/-; 8.5000/- 0/2/289 Yes
rs121912615-A/C; SI AR. In compound heterozygosity state Sucrase-isomaltase deficiency (PMIM:222900). Single gene; Rare disorder. 0.0052/0.0004/0.0025; 13.0000/2.0651 0/3/283 No
rs200487396-G/A; COL12A1 AD Bethlem myopathy 2 (PMIM:616471); Single gene; Rare disorder. 0.0018/0.0002/-; 9.0000/- 0/1/279 No
rs143137713-G/C; GYG1 AR Polyglucosan body myopathy 2 (PMIM:616199). Single gene; Rare disorder. 0.0017/0.0004/-; 4.2500/- 0/1/287 No
rs148772854-C/T; RYR1 AR. The variant participates in compound heterozygosity.
Minicore myopathy with external ophthalmoplegia 
(PMIM:255320). Single gene; Rare disorder. 0.0017/0.006/0.0015; 0.2833/1.1243 0/1/290 No
rs61757582-G/A; DHCR7 AR Smith-Lemli-Opitz syndrome (PMIM:270400). Single gene; Rare disorder. 0.0018/0.0002/-; 9.0000/- 0/1/284 Yes
rs61754375-G/A; TYR AR Tyrosinase-negative oculocutaneous albinism, Type IA (PMIM:203100). Single gene; Rare disorder. 0.0017/0.0002/-; 8.5000/- 0/1/286 Yes
rs61753185-G/A; TYR AR Tyrosinase-negative oculocutaneous albinism, Type IA (PMIM:203100). Single gene; Rare disorder. 0.0017/0.0004/0.0005; 4.2500/3.3730 0/1/290 Yes
rs104894313-C/T; TYR AR Oculocutaneous albinism type 1B (PMIM:606952). Single gene; Rare disorder. 0.0017/0.002/0.0049; 0.8500/0.3476 0/1/285 No
rs121434513-G/C; PNKD AD Paroxysmal Nonkinesigenic Dyskinesia 1 (PMIM: 118800). Single gene; Rare disorder. 0.0017/0.0002/0.0005; 8.5000/3.3531 0/1/289 Yes
rs121964924-A/G; DPYS AR Dihydropyrimidinase deficiency (PMIM:222748). Single gene; Rare disorder. 0.0017/0.0002/0.0020; 8.5000/0.8424 0/1/289 Yes
rs28940872-C/T; ACADS AR. This variant is seen in compound heterozygosity.
Short-chain acyl-CoA dehydrogenase (SCAD) 
deficiency (PMIM:606885). Single gene; Rare 
disorder.
0.0017/0.0002/0.0015; 8.5000/1.1251 0/1/289 Yes
rs148211042-C/T; ABCB6 AD Pseudohyperkalemia, familial, 2, due to red cell leak (PMIM:609153). Single gene; Rare disorder. 0.0017/0.0002/0.0010; 8.5000/1.6882 0/1/290 No
rs58331765-C/T; ABCA4 AR Stargardt disease 1, Juvenile (PMIM:248200)
93. 
Single gene; Rare disorder. 0.0034/0.0028/0.0005; 1.2143/6.7460 0/2/288 Yes
rs35152987-C/A; HBD AR.
delta Thalassemia – it is usually associated with 
a single gene of HBD. It does not have clinical 
manifestation but is usually associated with beta 
thalassemia. Thalassemia is a rare disorder.
0.0052/0.001/0.0086; 5.2000/0.6075 0/3/287 No
rs114368325-G/A; CYP24A1 AR. This variant is seen in compound heterozygosity.
Idiopathic hypercalcemia of infancy or 
hypercalcemia, infantile, 1; hcinf1 (PMIM:143880). 
Single gene; Rare disorder.
0.0017/0.0004/0.0005; 4.2500/3.3730 0/1/290 No
rs538881762-C/T; TENM4 AD
Tremor, hereditary essential, 5 (ETM5). 
(PMIM:616736). Single gene. GARD lists ETM as 
NOT a rare disorder but lists the subtypes as rare.
0.0018/0.0006/-; 3.0000/- 0/1/276 No
rs116100695-G/A; PKLR AR Pyruvate kinase deficiency of red cells (PMIM:266200). Single gene; Rare disorder. 0.0034/0.0016/0.0096; 2.1250/0.3547 0/2/289 Yes
rs6063-C/T; FGG AR. Found in double heterozygosity Fibrinogen Milano XII, digenic; Dysfibrinogenemia (PMIM:616004). Three genes. Rare disorder. 0.0052/0.0028/0.0050; 1.8571/1.0328 0/3/286 No
rs121908736-G/A; ADA AR, SM. The variant can also occur in compound heterozygous state
Partial adenosine deaminase deficiency 
(PMIM:102700). Single gene; Rare disorder. 0.0035/0.0018/0.0005; 1.9444/6.9444 0/2/285 Yes
rs41295338-G/T; TGM1 AR AR congenital ichthyosis 1 (PMIM:242300). Single gene; Rare disorder. 0.0034/0.0022/0.0060; 1.5455/0.5627 0/2/288 Yes
rs28941785-C/T; CTH AR. Cystathioninuria (PMIM:219500). Single gene; Rare disorder. 0.0035/0.0026/0.0065; 1.3462/0.5347 0/2/281 Yes
rs77010315-C/A; SLC36A2 AR, DR Iminoglycinuria, digenic (PMIM:242600). Single gene; Rare disorder. 0.0076/0.005/0.0025; 1.5200/3.0159 0/4/258 No
rs56208331-G/A; GATA4 AD Tetralogy of fallot; TOF. (PMIM:187500). Single gene; Rare disorder. 0.0034/0.0034/0.0025; 1.0000/1.3503 0/2/289 Yes
rs121908970-C/T; MYO15A AR. The variant was seen in hemizygosity state.
Deafness, with Smith-Magenis syndrome (PMIM: 
600316). Single gene; Rare disorder. 0.0018/0.001/0.0010; 1.8000/1.7875 0/1/274 No
rs34324426-C/T; PEX6 AR. The variant is in compound heterozygosity state.
Heimler syndrome 2 (PMIM:616617). Single gene; 
Rare disorder. 0.0017/0.001/0.0015; 1.7000/1.1243 0/1/290 No
rs104893836-T/C; GNRHR AR. The variant is in compound heterozygosity state.
Hypogonadotropic hypogonadism 7 without 
anosmia. (PMIM:146110). Single gene; Rare 
disorder.
0.0017/0.0012/0.0055; 1.4167/0.3069 0/1/290 Yes
rs5907-G/A; SERPIND1 AD Thrombophilia due to Heparin cofactor II deficiency (PMIM:612356). Single gene. Inherited disorder 0.0017/0.0012/-; 1.4167/- 0/1/290 No
rs113418909-A/T; SERPINA6 AR,AD Corticosteroid-binding globulin deficiency (PMIM:611489). Single gene; Rare disorder. 0.0017/0.0014/0.0045; 1.2143/0.3751 0/1/290 No
Continued
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dbSNP; Ref/risk; gene
Inheritance mode (AD:autosomal 
dominant; AR:autosomal recessive; 
MF:multifactorial)
Disorder (PMIM); No of OMIM-listed genes for 
the disorder; annotation pertaining to whether 
the disorder is rare or common$
RAFs: KWT/1KGP/GME; Ratios of 
RAFs: KWT-1KGP/KWT-GME
Carrier status in 
Kuwaiti exomes 
(rr/rR/RR)
Disorder seen in 
CAGS populations 
(YES/NO)?
rs121909293-C/T; CTRC AD
Pancreatitis, chronic, susceptibility to 
(PMIM:167800). 5 genes. Hereditary Pancreatitis, 
that leads to chronic form, as rare disorder.
0.0017/0.0016/-; 1.0625/- 0/1/290 No
rs137941190-C/T; DCPS AR. Found in compound heterozygous state.
Al-raqad syndrome (PMIM:616459). Single gene; 
Rare disorder. 0.0017/0.002/0.0005; 0.8500/3.3730 0/1/288 No
rs28940885-C/T; GALE AR/AD heterogeneity Galactose Epimerase Deficiency (PMIM:230350). Single gene; Rare disorder. 0.0017/0.002/0.0025; 0.8500/0.6751 0/1/290 Yes
rs73015965-A/G; PLG AR. Participates in compound heterozygosity
Plasminogen deficiency, type I (PMIM:217090). 
Single gene; Rare disorder. 0.0017/0.0022/0.0006; 0.7727/2.8286 0/1/289 No
rs200879436-T/C; CEP152 AR. The variant is seen in compound heterozygous state
Seckel syndrome 5 (PMIM:613823). Single gene; 
Rare disorder. 0.0017/0.0034/0.0015; 0.5000/1.1251 0/1/288 No
DRUG RESPONSE (n = 1)
rs61742245-C/A; VKORC1 AD
Warfarin resistance (PMIM:122700). Single gene; 
Polymorphisms in other genes, some of which 
have not been identified, have a smaller effect on 
warfarin metabolism. Rare disorder. Poor quality 
of anticoagulation with warfarin has been reported 
across Kuwait94
0.0104/0.0004/0.0137; 26.0000/0.7619 1/4/284 No
C. Risk Factor and rare disorders
rs139512218-G/T; SPRY4 AD
Hypogonadotropic hypogonadism 17 with 
or without anosmia (PMIM: 615266). Single 
gene. CHH is a rare reproductive disorder but 
multifactorial (involving genes of FGF pathway).
0.0035/0.0024/0.0010; 1.4583/3.4757 0/2/282 No
D. RISK FACTORS (n = 9) – Common or multifactorial complex disorders
rs11554495-C/A; KRT8 AR
Cirrhosis, cryptogenic (PMIM:215600). Two genes. 
ClinVar annotation is pathogenic but we annotate it 
as risk factor as this disorder is probably common. 
GARD does not list this as rare disorder as it affects 
more than 600,000 people in USA
0.0053/0.001/0.0027; 5.3000/1.9910 0/3/281 No
rs1800553-C/T; ABCA4 AD
Macular degeneration, age-related, 2 (AMD2), 
susceptibility to (PMIM:153800). Single gene; 
however, AMD is a complex trait. GARD lists this 
as NOT a rare disorder. ClinVar annotates this as 
pathogenic’; however, it is a susceptibility variant for 
a complex trait and hence it is risk factor.
0.0241/0.0032/0.0211; 7.5313/1.1396 1/12/278 No
rs11909217-C/T; LIPI AD
Susceptibility to Hypertriglyceridemia, Familial. 
(PMIM: 145750). Two genes -LIPI and APOA5. 
Arab study reports a different variant 3’ UTR C > G 
from APOC395. This is an inherited common 
disorder.
0.0172/0.006/0.0131; 2.8667/1.3138 0/10/280 Yes
rs114817817-C/T; SRGAP1 AD
Thyroid cancer, nonmedullary 2, susceptibility to 
(PMIM:188470). Three genes. Most common form 
of thyroid cancer.
0.0017/0.0006/0.0070; 2.8333/0.2412 0/1/285 Yes
rs72470545-G/A; HTRA2 AD
Parkinson disease 13, Autosomal Dominant, 
susceptibility to (PMIM: 610297). Single gene. It is a 
complex neuro-degenerative disorder.
0.0069/0.0036/0.0070; 1.9167/0.9789 0/4/287 No
rs28932472-G/C; POMC AR,AD,MF
Obesity, early-onset, susceptibility to (PMIM: # 
601665). Several genes. Common disorder. Arab 
study reports another variant rs1042713 (Arg16Gly) 
in ADRB2 gene96 for this disorder; which is 
associated with susceptibility to nocturnal asthma in 
OMIM and our study.
0.0017/0.0024/0.0005; 0.7083/3.3730 0/1/287 Yes
rs34911341-C/T; GHRL AR,AD,MF Obesity, susceptibility to (PMIM: 601665). Several genes. Common disorder. 0.0017/0.0026/0.0035; 0.6538/0.4823 0/1/290 Yes
rs138292988-G/A; AP1S3 AD
Psoriasis 15, pustular, susceptibility to 
(PMIM:616106). Single gene. Psoriasis is NOT 
a rare disorder; pustular psoriasis is a rare form 
Psoriasis. Susceptibility is the keyword.
0.0017/0.0024/0.0015; 0.7083/1.1251 0/1/289 No
rs116107386-A/C; AP1S3 AD
Psoriasis 15, pustular, susceptibility to 
(PMIM:616106). Single gene. Psoriasis is NOT 
a rare disorder; pustular psoriasis is a rare form 
Psoriasis.
0.0018/0.003/0.0050; 0.6000/0.3575 0/1/279 No
Table 3. 46 rare and deleterious variants (pathogenic and risk factors)@ seen in Kuwaiti Exomes. All the 46 
variants were seen annotated in OMIM and ClinVar for clinical significance. @Clinical significance of a variant 
was checked by way of using the evidences presented in OMIM and ClinVar (see Methods). $Various resources 
that were examined to ascertain whether the disorder is rare or common: Catalogue of Transmission Genetics 
in Arabs (available at http://cags.org.ae/ctga/), Genetic and Rare Disease (GARD) Information Centre (available 
at https://rarediseases.info.nih.gov/diseases/), Genetics Home Reference (available at https://ghr.nlm.nih.gov/), 
Medscape (available at https://geneaware.clinical.bcm.edu/GeneAware/AboutGeneAware/DiseaseSearch.aspx) 
and literature.
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Chr:Position
dnSNP ID; 
variant change: 
amino acid 
change Gene
KWT_RAF/1KGP_ RAF/GME_RAF; 
Ratio KWT-1KGP/KWT-GME RAFs
Ref_
risk
Affecting 
Allele(s) for 
the drug 
response
Drug response to which 
is impacted Disease/Condition
4:3006043
rs1024323; 
c.425C > T: 
Ala142Val
GRK4 0.3718/0.3732/0.3887; 0.9962/0.9565 C_T
T atenolol Hypertension
CC metoprolol Hypertensive Nephrosclerosis
CC metoprolol Hypertensive Nephrosclerosis
17:7579472
rs1042522; 
c.215C > G: 
Pro72Arg
TP53 0.4425/0.5429/.; 0.8150/. G_C CG + GG cisplatin; paclitaxel Stomach neoplasms
5:148206440
rs1042713; 
c.46A > G: 
Arg16Gly
ADRB2 0.5513/0.5244/0.5645; 1.0513/0.98 G_A
AA terbutaline Asthma
AA salmeterol Asthma
A Beta Blocking Agents Heart Failure
G hydrochlorothiazide Hypertension
A indacaterol Chronic obstructive pulmonary disease
5:148206473
rs1042714; 
c.79C > G: 
Gln27Glu
ADRB2 0.2246/ 0.2053/0.2412; 1.094/0.9312 G_C
GG terbutaline Asthma
G Beta Blocking Agents Heart Failure
C indacaterol Chronic obstructive pulmonary disease
15:75012985
rs1048943; 
c.1384A > G: 
Ile462Val
CYP1A1 0.0653/0.1334/0.0619; 0.4895/1.0542 T_C C warfarin warfarin
10:96798749
rs10509681; 
c.1196A > G: 
Lys399Arg
CYP2C8 0.1198/0.0457/0.1047; 2.6197/1.1438 T_C
C rosiglitazone Diabetes
C repaglinide Diabetes
C paclitaxel Cancer(chemotherapy)
7:75615006
rs1057868; 
c.1508C > T: 
Ala503Val
POR 0.2609/0.2861/0.2808; 0.9120/0.9292 C_T CT + TT tacrolimus Kidney transplantation
17:37879588
rs1136201; 
c.1963A > G: 
Ile655Val
ERBB2 0.0975/0.1214/0.1255; 0.8032/0.7770 A_G G trastuzumab Breast cancer
10:96827030
rs11572080; 
c.416G > T: 
Arg139Lys
CYP2C8 0.1237/0.0457/0.1013; 2.7054/1.2211 C_T
T paclitaxel Cancer(chemotherapy)
T rosiglitazone Diabetes
T repaglinide Diabetes
T paclitaxel Neoplasms
2:21263900
rs1367117; 
c.293C > T: 
Thr98Ile
APOB 0.1448/0.1693/0.1727; 0.8553/0.8386 G_A
AG Irbesartan Hypertension
GG Irbesartan Hypertension
11:113270828
rs1800497; 
c.2137G > A: 
Glu713Lys
ANKK1 0.1713/0.3257/0.1908; 0.5259/0.8975 G_A
A risperidone Schizophrenia
A lithium Bipolar disorder
A antipsychotics Schizophrenia
A Drugs used in nicotine dependence Tobacco use disorder
AA + AG aripiprazole Schizophrenia
AA methadone Heroin dependence
5:148206885
rs1800888; 
c.491C > T: 
Thr164Ile
ADRB2 0.0121/0.0040/0.0156; 3.0325/0.7759 C_T
CT terbutaline Asthma
T Beta Blocking Agents Heart Failure
3:124456742
rs1801019; 
c.638G > C: 
Gly213Ala
UMPS 0.1632/0.1859/0.1767; 0.8780/0.9236 G_C C fluorouracil Colonic neoplasms
4:3039150
rs1801058; 
c.1457T > C: 
Val486Ala
GRK4 0.2293/0.3067/0.292; 0.7476/0.7079 T_C
T atenolol Hypertension
CT metoprolol Hypertensive Nephrosclerosis
CT metoprolol Hypertensive Nephrosclerosis
1:237048500
rs1805087; 
c.2756A > G: 
Asp919Gly
MTR 0.2603/0.2183/0.2021; 1.1929/1.2881 A_G A
folic acid; 
hydroxychloroquine; 
methotrexate; 
sulfasalazine
Rheumatoid Arthritis
7:55229255
rs2227983; 
c.1562G > A: 
Arg521Lys
EGFR 0.2759/0.2921/0.2784; 0.9443/0.9907 G_A A cetuximab Colorectal neoplasms
22:42525772
rs28371706; 
c.320C > T: 
Thr107Ile
CYP2D6 0.0446/0.0591/.; 0.7553/.
G_A A codeine Sickle Cell Anemia
AA + AG nevirapine HIV
Continued
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(mQTLs) in a cohort from Middle Eastern population48; this variant was seen in 29 of the Kuwaiti exomes in the 
heterozygous form.
Missense variants mapping to drug-binding domains and were of pharmacogenomic rele-
vance. We identified 21 missense SNVs that mapped to a set of 130 drug-binding domains reported in litera-
ture49 and were annotated in PharmGKB50 (Table 4). These 21 variants had impact on the efficacy of drugs used 
largely for treating common disorders (such as heart failure, hypertension, Chemotherapy, neoplasms, diabetes, 
nephrosclerosis, rheumatoid arthritis, asthma, pulmonary diseases, schizophrenia, tobacco use disorder, heroin 
dependence, sickle-cell anemia, and HIV). Furthermore, literature survey revealed that 7 of these 21 pharmacog-
enomic variants were associated with complex disorders in Arab studies (Table 5).
SAFD variants and their clinical relevance. For 230 of the 6,186 SAFD variants, ClinVar database pro-
vided annotation relating to clinical significance (Supplementary Fig. S5 and Supplementary Table S7). These 
230 variants were from 186 unique genes, for 162 of which Inheritance patterns were known; 91 were AR and 63 
were AD. 206 of these 230 variants were benign or likely benign. The disorders related to the genes harbouring 
the benign variants were often single-gene disorders and familial, hereditary and congenital. The 24 non-benign 
variants (Table 6) were from 21 unique genes associated with 20 unique disorders.
Seven of these 24 non-benign SAFD variants were seen annotated in ClinVar as “Pathogenic”; however, either 
the associated disorder was common/complex or more prevalent in the study population or the patient carrying 
the variant was annotated in OMIM as susceptible to the disorder (which is usually a common disorder). Going 
by the practice that “pathogenic” variants are related to Mendelian disorders, we considered the variants associ-
ated with common disorders as risk factors. (i) rs1800435_G > C (MAF_KWT:12.41%; MAF_1KGP:6.4%) asso-
ciated with “Aminolevulinate dehydratase, alad*1/alad*2 polymorphism susceptibility to lead poisoning ALAD 
porphyria”. ClinVar annotated this as pathogenic based on literature evidence and likely benign based on clinical 
testing. It increases the risk for lead poisoning. ALAD porphyria is a very rare genetic metabolic disease; however, 
quoting from the CDC report on lead poisoning – “There are approximately half a million U.S. children ages 1–5 
with blood lead levels above 5 micrograms per deciliter (µg/dL), the reference level at which CDC recommends 
public health actions be initiated”, lead poisoning is no longer a rare disorder. Susceptibility is the keyword, and 
we reannotated this variant as risk factor. (ii) rs5030737 (MAF_KWT:7.90%; MAF_1KGP:2.8%) associated with 
Mannose-binding lectin deficiency, which is a complex trait. ClinVar annotated the variant as pathogenic based 
on literature reference; since we associate “pathogenic” to Mendelian disorders, we reannotated this variant as risk 
factor. (iii) rs121918530 (MAF_KWT:1.03%; MAF_1KGP:0.04%)associated with coronary artery disease/myo-
cardial infarction, which is a complex multifactorial disorder. ClinVar annotated this variant as pathogenic based 
on literature evidence and likely benign based on clinical testing. since we associate “pathogenic” to Mendelian 
disorders, we reannotated this variant as risk factor. (iv) rs5030739 (MAF_KWT:8.42%; MAF_1KGP:2.32%) 
associated with “Prostate cancer hereditary 2, susceptibility to” (Complex trait). ClinVar annotated this variant 
as pathogenic based on literature evidence and benign based on clinical testing. The cited literature suggested 
increased risk of prostate cancer; ‘susceptibility to’ was the keyword. Thus, this variant was considered as risk 
factor. It was also the case that this variant has to appear in compound heterozygosity with the next listed variant 
of rs4792311. We reannotated this variant as risk factor. (v) rs4792311 (MAF_KWT:35.52%; MAF_1KGP:21.5%) 
associated with “Prostate cancer hereditary 2, susceptibility to” (Complex trait). ClinVar annotated this variant 
Chr:Position
dnSNP ID; 
variant change: 
amino acid 
change Gene
KWT_RAF/1KGP_ RAF/GME_RAF; 
Ratio KWT-1KGP/KWT-GME RAFs
Ref_
risk
Affecting 
Allele(s) for 
the drug 
response
Drug response to which 
is impacted Disease/Condition
4:2990499
rs2960306; 
c.194G > T: 
Arg65Leu
GRK4 0.3711/0.3125/0.3620; 1.1875/1.0250 G_T
T atenolol Hypertension
GT + TT metoprolol Hypertensive Nephrosclerosis
TT metoprolol Hypertensive Nephrosclerosis
19:41522715
rs3211371; 
c.1459C > T: 
Arg487Cys
CYP2B6 0.0423/0.0535/0.0624; 0.7896/0.6767 C_T
TT nevirapine HIV
TT methadone Heroin dependence
19:41512841
rs3745274; 
c.516G > T: 
Gln172His
CYP2B6 0.2759/0.3157/0.3026; 0.8738/0.9116 G_T
TT efavirenz HIV
T nevirapine HIV
TT methadone Heroin dependence
GT + TT nevirapine HIV
T nevirapine HIV
GT nevirapine HIV
TT nevirapine HIV
TT nevirapine HIV
GT nevirapine HIV
TT nevirapine HIV
1:230845794 rs699; c.803T > C: Met268Thr AGT 0.583/0.7051/0.5534; 0.8268/1.0535 A_G G Antihypertensives Hypertension
Table 4. 21 missense variants mapping to drug-binding domains and of pharmacogenomic relevance (efficacy, 
dosage toxicity).
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as pathogenic based on literature evidence and benign based on clinical testing. The cited literature suggested 
increased risk of prostate cancer; ‘susceptibility to’ is the keyword. Thus, this variant was considered as risk factor. 
It was also the case that this variant had to appear in compound heterozygosity with the previous listed variant 
of rs5030739. We reannotated this variant as risk factor. (vi) rs1801483 (MAF_KWT:3.78%; MAF_1KGP:0.42%) 
associated with Diabetes mellitus type 2, non-insulin dependent (a multifactorial complex disorder). ClinVar 
annotated the variant as pathogenic (based on literature evidence). Considering that we associate “pathogenic” 
only with Mendelian disorder, we reannotated the variant as risk factor. (vii) rs34719006 (MAF_KWT:2.58%; 
MAF_1KGP:0.18%) associated with Cholestasis of pregnancy, which is a most common liver disease unique 
to pregnancy. (Complex trait). ClinVar annotated this variant as pathogenic based on evidence from literature 
study and annotated as with conflicting evidence between likely benign (clinical testing), uncertain significance 
(Clinical testing). Considering that we associate “pathogenic” only with Mendelian, we reannotated this variant 
as risk factor.
This set of 24 SAFD variants with clinical significance was distributed onto (a) A set of 2 pathogenic variants 
(rs61757294 and rs61751507) with AR mode inheritance; the MAF of these two variants in Kuwaiti exomes were 
uncharacteristic of pathogenic variants (see above for more details); (b) A set of 4 drug response variants one of 
which was AR); (c) A set of 14 risk variants and 2 protective variants for complex traits (3 were AR); and (d) A set 
of two variants associated with phenotype traits through GWAS studies. Five of the disorders associated with the 
SAFD variants were seen annotated in CAGS as observed in Arab countries (see Table 6).
Assessing the Loss-of-Function SAFD Variants for clinical significance. We had identified 26 LoF 
SAFD variants (Supplementary Table S4); as many as 15 of these were stop-gain, seven were start-loss and the 
remaining four were splice site mutations. None of these 26 SAFD LoF variants was seen annotated for disorder 
in OMIM; however, the GWAS Catalog51 listed one of these variants namely rs2228015-C from CCR7 gene as 
associated with the complex phenotype trait of lymphocyte counts (at genome-wide significant p-value of 6E-09).
CAGS disorders for which the OMIM-listed causal variants were seen in Kuwaiti exomes. We 
further examined the CAGS database for disorders observed in Kuwait at any incidence rate and for disorders 
seen in any of the Arab countries at incidence rates of ≥11 per 100,000. CAGS database provided the Phenotype 
MIM number using which we retrieved the OMIM-reported causal variants and checked for their occurrences 
in Kuwaiti exomes. For 25 disorders, the OMIM-reported variants were seen in Kuwaiti exomes (Table 7); 
eight of these 25 disorders had already been seen in the analysis for functional variants. Except in one instance 
(rs1800858), all the variants were missense. 13 of these variants were “pathogenic” and the remaining 12 were 
“risk factor” variants. 18 of these disorders were observed in Kuwait and the remaining in other Arab countries.
Pharmaco-
genomic 
variant Gene
KWT_
RAF/1kGP_RAF/
GME_RAF 
Ratio 
KWT_1KGP/Ratio 
KWT_GME
Ref_risk 
allele
Drug to which 
response is reported
Disorder treated 
with the drug
Disorder with which Arab 
studies associate the variant
rs1805087 MTR 0.260/0.218/0.202 1.1929/1.2881 A_G
Folic acid; hydroxy-
chloroquine; 
methotrexate; 
sulfasalazine.
Rheumatoid arthritis
Autism – North Iran97. GG seems 
to be the risk factor. GG seems to 
be the risk factor.  Complex trait.
rs1042522 TP53 0.443/0.543/- 0.8150/- G_C Cisplatin; paclitaxel Stomach neoplasms Susceptibility to Breast Cancer in Tunisia98. Complex trait.
rs1800497 ANKK1 0.1713/0.326/0.191 0.5259/0.8975 G_A Risperidone Schizophrenia
Risk of Schizophrenia in 
Egyptians99. CC and CT 
genotypes are the risk factors. 
Complex trait.
rs1801058 GRK4 0.229/0.307/0.292 0.7476/0.7079 T_C Atenolol Hypertension
Risk of myocardial infarction 
among hypertensive subjects in 
Jordan100. Complex trait.
rs699 AGT 0.583/0.705/0.553 0.8268/1.0535 A_G Anti-hypertensive Hypertension
Reduced life-span through 
genetic susceptibilities to both 
Essential Hypertension and 
Myocardial Infarcation in UAE101. 
Complex trait.
rs1042713 ADRB2 0.551/0.5244/0.565 1.0513/0.98 A_G Terbutaline Asthma
Susceptibility to early onset 
obesity, insulin resistance etc. 
in Saudi Arabia102. the subjects 
who carry Gly16 homozygote 
genotype are in higher risk. 
Complex trait.
rs1042714 ADRB2 0.225/0.205/0.241 1.0941/0.9312 G_C Terbutaline Asthma
Associated with coronary artery 
disease/myocardial infarction 
in Saudi Arabia103,104. both the 
C/G and G/G genotypes are 
significantly associated with 
CAD. Complex trait.
Table 5. Subset of 7 of the identified pharmacogenomic variants (from Table 4) that were also reported in Arab 
studies as relating to complex disorders.
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Chr: Position; dbSNP_ID_
Ref_Alt; Gene
KUWAITI 1KGP gnomAD
Inheritance mode
Disease name; PMIM; 
number of OMIM listed 
genes; Is the disorder seen 
in Arab population?@KWT_MAF Max_Pop (MAF)
1KGP_
MAF Max_Pop (MAF)
gnomAD_
MAF
Max_Pop 
(MAF)
A. 2 “Pathogenic” variants as per ClinVar annotation
8:143994266; rs61757294_ 
A_G c.1157T > C; 
p.Val386Ala CYP11B2
0.1519 This has DR mode of 
inheritance – both this and 
another variant rs289316 need to 
be homozygous; hence this higher 
MAF is alright though the variant is 
“pathogenic”.
KWS (0.1698) 0.0531 EUR (0.1093) 0.0846 ASJ (0.1163)
DR (both 
rs61757294 and 
rs28931609 need to 
be homozygous)
Corticosterone 
methyloxidase type 2 
deficiency. PMIM: 610600; 
Single gene. Rare Genetic 
disorder. Yes, disorder seen 
in Arab country.
10:101829514 rs61751507_ 
C_T c.533G>A; 
p.Gly178Asp CPN1
0.0747 (high MAF for “pathogenic” 
variant). ClinVar annotates this 
variant as pathogenic based on one 
literature publication which reports 
this variant in just one patient. Thus, 
it is possible that the significance is 
of insufficient evidence and that the 
variant may become “likely benign”.
KWS (0.0981) 0.0266 AMR (0.0634) 0.0423 AMR (0.0668) AR
Carboxypeptidase N 
deficiency PMIM: 212070 
Single gene. Familial 
Carboxypeptidase N 
deficiency is a rare disorder.
B. 4 Drug response variants as per ClinVar annotation
16:31105945 rs61742245_ 
C_A c.106G>T; p.Asp36Tyr 
VKORC1
0.0104 KWB (0.0294) 0.0004 EUR (0.0010) 0.0024 ASJ (0.0384) AD
Warfarin resistance PMIM: 
122700 Multiple genes 
and rare disorder. Appears 
already in Table 3 as drug 
response.
8:18257854 rs1801280_ T_C 
c.208G>A; p.Asp70Asn 
NAT2
0.3927 KWP (0.3879) 0.2927 EUR (0.4493) 0.3821 FIN (0.4668)
AR Forms part 
of NAT2*5B 
haplotype
Slow acetylator due to 
N-acetyltransferase 
enzyme variant. Toxicity 
to the drugs of cisplatin or 
cyclophosphamide. PMIM: 
243400 Yes, disorder seen in 
Arab country.
10:96702047 rs1799853_ 
C_T c.430C>T; p.Arg144Cys 
CYP2C9
0.1181 KWS (0.1262) 0.0479 EUR (0.1243) 0.0926 ASJ (0.1357) AD Warfarin sensitivity PMIM: 122700 Multiple genes.
19:15990431 rs2108622_ 
C_T c.1297G>A; 
p.Val433Met CYP4F2
0.4102 KWS (0.4541) 0.2368 SAS (0.4131) 0.2735 SAS (0.3978) Na
Acenocoumarin response – 
Dosage. Warfarin sensitivity. 
PMIM: 122700 Multiple 
genes.
C. 14 Risk factor variants
C. 1. 7 Risk factor variants as per ClinVar annotation for complex disorders
2:138759649 rs11558538_ 
C_T c.314C>T; p.Thr105Ile 
HNMT
0.1259 KWS (0.1495) 0.0595 SAS (0.1053) 0.1008 FIN (0.1601) AD
Asthma, susceptibility to; 
PMIM: 600807 Multiple 
genes. Yes, disorder seen in 
Arab country.
4:100268190 rs283413_ C_A# 
$ c.232G>T; p.Gly78Arg 
ADH1C
0.0653 KWP (0.1071) 0.0072 SAS (0.0174) 0.0157 ASJ (0.0633) IC,Mu
Parkinson’s disease, 
susceptibility to; PMIM: 
168600 Multiple genes.
5:95751785 rs6232_ T_C 
c.661A>G; p.Asn221Asp 
PCSK1
0.0594 KWB (0.0909) 0.0210 SAS (0.0501) 0.0390 SAS (0.0659) ?
Obesity, susceptibility 
to, Body mass index 
quantitative trait locus 12 
PMIM: 612362. OMIM lists 
single gene but in reality, 
BMI is associated with 
multiple genes.
10:64415184 rs7076156_ 
G_A# & c.1130-972G>A; 
p.Ala62Pro ZNF365
0.3351 KWS (0.4450) 0.1288 EUR (0.2734) 0.2044 ASJ (0.2795) Na
Uric acid nephrolithiasis, 
susceptibility to; PMIM: 
605990. OMIM lists 
single gene but this is a 
multifactorial disorder.
14:104165753 rs861539_ 
G_A c.1849-1239G>A; 
p.Thr241Met XRCC3
0.3864 KWS (0.4450) 0.2169 EUR (0.3936) 0.2904 ASJ (0.4015) AD
Cutaneous malignant 
melanoma 6, susceptibility 
to PMIM: 613972. OMIM 
lists single gene but this is a 
multifactorial disorder.
17:5485367 rs12150220_ 
A_T c.464T>A; p.Leu155His 
NLRP1
0.4377 KWP (0.4643) 0.1921 EUR (0.4443) 0.3674 ASJ (0.4744) AR
Vitiligo-associated multiple 
autoimmune disease 
susceptibility 1; PMIM: 
606579. OMIM lists 
single gene but this is a 
multifactorial disorder.
17:48437456 rs6504649_ 
C_G c.2402C>G; 
p.Thr801Arg XYLT2
0.4414 KWB (0.4706) 0.2510 EUR (0.4006) 0.3312 ASJ (0.4536) AR
Pseudoxanthoma elasticum, 
modifier of severity; PMIM: 
264800. OMIM lists multiple 
genes: XYLT1, XYLT2, 
ABCC6. Yes, disorder seen in 
Arab country.
Continued
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Chr: Position; dbSNP_ID_
Ref_Alt; Gene
KUWAITI 1KGP gnomAD
Inheritance mode
Disease name; PMIM; 
number of OMIM listed 
genes; Is the disorder seen 
in Arab population?@KWT_MAF Max_Pop (MAF)
1KGP_
MAF Max_Pop (MAF)
gnomAD_
MAF
Max_Pop 
(MAF)
C. 2. 7 Risk factor variants as per our inference but annotated as “pathogenic” in ClinVar annotation
9:116153891 rs1800435_ 
C_G c.177G>C; p.Lys59Asn 
ALAD
0.1241 KWB (0.1912) 0.0635 SAS (0.1585) 0.0830 ASJ (0.2207) AR
Aminolevulinate 
dehydratase, ALAD*1/
ALAD*2 allele at this 
position associated with 
susceptibility to lead 
poisoning. PMIM: 612740. 
Lead poisoning is becoming 
a common disease. Single 
gene.
10:54531242 rs5030737_ 
G_A c.154C>T; p.Arg52Cys 
MBL2
0.0790 KWP (0.0902) 0.0272 EUR (0.0596) 0.0558 ASJ (0.1032) AD
Mannose-binding lectin 
deficiency. PMIM: 614372 
Single gene. Complex trait
15:100230557 rs121918530_ 
A_G c.782A>G; 
p.Asn261Ser MEF2A
0.0103 KWB (0.0294) 0.0004 EUR (0.0020) 0.0008 NFE (0.0015) AD
Coronary artery disease/
myocardial infection 
PMIM: 608320 Single gene. 
Complex trait
17:12899902 rs5030739_ 
C_T c.1621G>A; 
p.Ala541Thr ELAC2
0.0842 KWS (0.1055) 0.0232 SAS (0.0501) 0.0349 ASJ (0.0510)
AR or AD? 
Has to be seen 
in compound 
heterozygous 
state with another 
variant rs4792311.
Susceptibility to Prostate 
cancer, hereditary, 2′ 
PMIM: 614731 Single gene. 
Complex trait
17:12915009 rs4792311_ 
G_A c.650C>T; p.Ser217Leu 
ELAC2
0.3552 KWP (0.3611) 0.2145 EUR (0.3151) 0.2742 ASJ (0.3699)
AR or AD? 
Has to be seen 
in compound 
heterozygous 
state with the 
previous variant of 
rs5030739.
Susceptibility to Prostate 
cancer, hereditary, 2′; 
PMIM: 614731 Single gene. 
Complex trait
17:79767715 rs1801483_ 
G_A c.118G>A; p.Gly40Ser 
GCGR
0.0378 KWS (0.0505) 0.0042 EUR (0.0149) 0.0075 ASJ (0.0120) AD
Diabetes mellitus type 2, 
non-insulin dependent; 
PMIM: 125853; Multiple 
genes. Multifactorial 
complex disorder. Yes, 
disorder seen in Arab 
country.
18:55373793 rs34719006_ 
C_T c.208G>A; p.Asp70Asn 
ATP8B1
0.0258 KWS (0.0413) 0.0018 AFR (0.0045) 0.0031 ASJ (0.0096) AD
Cholestasis of pregnancy; 
PMIM: 147480 Single gene. 
However, it is the most 
common liver disease unique 
to pregnancy. Complex trait.
D. 2 variants associated with complex traits by GWAS studies followed by clinical testing as per ClinVar annotation
2:27730940 rs1260326_ C_T# 
c.1337T>C; p.Leu446Pro 
GCKR
0.3945 KWS (0.4352) 0.2933 EAS (0.4812) 0.3667 ASJ (0.5344) Not available
Fasting plasma glucose 
level quantitative trait locus 
5 PMIM: 613463 Single 
gene (but, FPG levels are 
associated with multiple 
genes).
11:68846399 rs35264875_ 
A_T c.1450A>T; 
p.Met484Leu TPCN2
0.1832 KWP (0.2260) 0.0996 SAS (0.2055) 0.1593 FIN (0.2980) Not available
Skin/hair/eye pigmentation, 
variation in, SHEP10 PMIM: 
612267; OMIM lists single 
gene (but, the variations in 
skin/hair/eye pigmentation 
variations are associated with 
multiple genes).
E. 2 Protective variants as per ClinVar annotation
4:100260789rs698_ T_C 
c.1048A > G; p.Ile350Val 
ADH1C This variant is in 
LD with the variant R271Q 
(corresponding to the 
variant listed in the next row 
rs1693482) that is responsible 
for the differences in 
enzymatic differences
0.3137 KWS (0.3515) 0.2143 EUR (0.4046) 0.3470 FIN (0.5169) Ic, Mu
Alcohol dependence, 
protection against; PMIM: 
103780. Multiple genes.
4:100263965 rs1693482_ 
C_T c.815G>A; 
p.Arg272Gln ADH1C
0.3296 KWS (0.3830) 0.2143 EUR (0.4046) 0.3462 FIN (0.5167) Ic, Mu
Alcohol dependence, 
protection against; PMIM: 
103780. Multiple genes.
Table 6. List of 24 SAFD variants annotated for clinical significance in ClinVar and OMIM. @Disorders 
relating to the following variants rs61757294 (CYP11B2, Pathogenic, DR, Corticosterone methyloxidase type 
2 deficiency). rs1801483 (GCGR, reannotated as risk factor, AD form T2D), rs11558538 (HNMT, Risk factor, 
AD, susceptibility to asthma), rs1801280 (NAT2, drug response, AR, Slow acetylator due to N-acetyltransferase 
enzyme variant) and rs6504649 (XYLT2, Risk Factor, AR, Pseudoxanthoma elasticum, modifier of severity) are 
seen annotated in CAGS as observed in many Arab countries.
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Scrutinization of the identified variants against Arab mutations reported in Arab stud-
ies. Analyses performed so far in the study indicated that disorders relating to 20 instances of rare & deleteri-
ous variants, 16 of which were pathogenic variants for rare disorders and 4 were risk factor variants for complex 
disorders (see Table 3), 7 instances of pharmacogenomic variants that were associated with complex disorders 
in Arab studies (see Table 5), 5 instances of SAFD variants (see Table 6), and 17 additional instances from the 
analysis of CAGS disorders were seen in Arab population (see Table 7). During the analysis, we also found in 
Kuwaiti exomes two recessive mutations (namely rs1801133 & rs1801131 from MTHFR – see Table 8) associated 
with recessive early onset of susceptibility to Type 2 diabetes in Arab population. We set upon to identify which 
of these variants were also reported in Arab studies for the corresponding disorder. Upon performing literature 
survey and manual examination of the bibliography data presented in CAGS database, these variants could be 
classified onto the following categories (Table 8): (a) 16 Instances where the OMIM-listed variants identified in 
Kuwaiti exomes were also reported as Arab mutations in Arab studies. 9 of these were pathogenic variants for rare 
disorder; 1 was drug response; and 6 were risk factors for complex disorders. (b) 7 Instances where the identified 
pharmacogenomic variants in Kuwaiti exomes were also observed as associated with disorders in Arab studies. 
These were drug response variants to complex disorders. (c) 12 instances of disorders where the genetic basis at 
SNV level had not been reported in Arab studies. 7 of these were pathogenic variants for rare disorders and 5 were 
risk factors for complex disorders. (d) 10 Instances where the Arab studies reported variants different from the 
OMIM-listed variants observed in Kuwaiti exomes; however, the Arab reported variants were from the same gene. 
The Arab variants were generally seen in OMIM but not in our exomes. Eight of these variants were pathogenic 
for rare disorders and two were risk factors for complex disorders. (e) 7 Instances of variants (from 4 disorders) 
where the Arab studies reported variants from genes different from those of the OMIM-listed variants observed 
in Kuwaiti exomes. In general, the different gene and the different mutations were listed in OMIM for the disorder 
but were not seen in Kuwaiti exomes. All the 7 variants were risk factors for complex disorders.
Identified variants and the associated complex disorders. Examining our in-house genome- 
wide association study (GWAS) data (on 1351 native Kuwaiti Arab individuals genotyped on Illumina 
HumanOmniExpress BeadChip and 1900 native Kuwaiti Arab individuals genotyped on Illumina 
HumanCardio-Metabo BeadChip) for the presence of the variants identified through exome analysis revealed 
that 27 of the identified OMIM-listed causal variants present in Kuwaiti exomes were also seen in the GWAS data. 
Allele frequencies and carrier distributions as seen in exomes data set and GWAS data set are presented (Table 9). 
13 of these 27 variants were associated with disorders observed in Arab studies. The 27 variants were pharmacog-
enomic (11), SAFD (9) and CAGS (5 + 2) variants for complex disorders. The allele frequencies among the data 
sets of Kuwait exome, Kuwait GWAS and GME were comparable with each other; and the carrier distributions 
were similar between the Kuwaiti exomes and GWAS data sets.
Discussion
In this study, exomes from 291 healthy, unrelated native Kuwaiti Arabs were analysed to identify 170,508 
SNVs and 3,341 indels. 12% of SNVs and 28% of indels were novel. One-third of the identified SNVs were 
population-specific, and 21.7% were ‘personal’ (observed in only one Kuwaiti exome and not seen in GME or 
1KGP), consistent with the results of other studies on ethnic populations, including those from Qatar44, Spain17 
and Denmark12. 53% of the identified SNVs were missense, and an average of 1.3% of the 14,557 SNVs that each 
person carried were predicted to affect protein function. Allele frequencies in 6,186 SAFD variants were signifi-
cantly different from those observed in 1KGP populations.
Recent population genetic analyses have demonstrated that humans harbour an abundance of rare & dele-
terious variations, with >80% of all coding variants having a frequency of ≤1%10,14,52. In this study, a majority 
(51%) of the identified SNVs in Kuwaiti exomes were rare. Of the identified 55,644 population-specific SNVs, 
only 138 were ‘common’, and the rest were ‘rare’ or ‘low-frequency’. Up to 60% of the population-specific vari-
ants were missense changes, and 51% of LoF variants were population-specific (some of which were polymor-
phic). These observations support the notion that coding variants with allele frequency of <1% show increased 
population-specificity and are enriched for functional variants13. Human populations have experienced recent 
explosive growth, expanding by at least three orders of magnitude over the past 400 generations; such a rapid 
recent growth along with weak purifying selection has increased the load of rare variants, many of which are 
deleterious and relevant for understanding disease risks14,16.
On average, nearly 10.4% of Kuwaiti population-specific variants found in every Kuwaiti individual were 
homozygous; this extent of homozygosity, which is higher than that observed in other ethnic populations (such 
as the value of 7.05% in Spanish17), reflects the higher rate of consanguinity practised among the Kuwaiti Arab 
population. The GME study26 demonstrated an increased burden of runs of homozygosity in Greater Middle East 
populations; our previous works had shown that Kuwaiti population is heterogeneous (placed between popula-
tions that have large amount of ROH and the ones with low ROH) with the KWS subgroup as highly endoga-
mous24. An average of 73 LoF variants (of which 4.5 were Kuwaiti-specific) were seen per individual. Observed 
disease-causing mutations failing to cause disease in at least a proportion of the individuals who carry them has 
been extensively discussed53. On an average, only 4.67% of Kuwaiti-specific LoF variants per individual were seen 
homozygous (as opposed to the expected 10.4%) and such a reduced homozygosity among LoF variants may 
explain the reduced penetrance.
Rare homozygous loss of function variants are supposed to exhibit strong signs of selective pressure. Of the 
genes harboring the identified 36 rare (MAF <2.0%) homozygous putative LoF variants observed in Kuwaiti 
exomes, only 8 were seen common with published list of inactivated genes from Icelanders42 and only 1 was 
common with the list from ExAC8. These findings suggest that the set of non-clinically relevant loss-of-function 
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SNPs from Kuwaiti 
exomes seen annotated 
in OMIM against 
the CAGS disorder; 
Ref > risk alleles Disorder
ClinVar annotation for the disorder
(CAGS OMIM Id)
Incidence 
Rates Inheritance
Carrier 
Frequencies
(rr/rR/RR) RAF(KWT/1KGP/GME)
Ratios (KWT-
1KGP /KWT-
GME)
A. 7 Pathogenic variants for rare disorders
rs12021720
C > T
p.Gly384Ser
DBT
Maple syrup urine disease, 
intermediate, type ii 
(PMIM:248600). It is a rare 
genetic disorder. OMIM lists 
single gene for the Type II MSUD
Pathogenic for the subtype. AR 5/67/218
0.1347/0.1082/0.12
The literature publication, cited in 
OMIM, reporting this variant as 
pathogenic, found it in compound 
heterozygosity with another variant 
[rs121965001] in the patient. 
Thus, the high MAF at one of the 
two variants of the compound 
heterozygotes is perhaps acceptable 
for pathogenic variant.
0.97/0.98
rs79204362
C > T
p.Arg368His
CYP1B1
Glaucoma, early-onset, digenic 
(PMIM: 231300). OMIM lists 
single gene. This is a rare disorder 
but reaches high prevalence in 
Saudi Arabian populations
Pathogenic 11–50 AR 0/6/284
0.0103/0.0042/0.0137
Incidence rate in Middle East is 
51–100 per 100,000 (i.e. 5 in 10,000); 
CTGA reports as high as 1 in 2,500 
in Saudi Arabian population. 
Accordingly, MAF is seen marginally 
higher at 1.03%
2.47/0.76
rs61732874
C > A
p.Ala744Ser
MEFV
Familial Mediterranean fever 
(PMIM: 249100). OMIM lists 
single gene. However, this can 
be a common disorder in certain 
populations.
Pathogenic/Likely Pathogenic 51–100 AR 0/9/278
0.0155/0.0018/0.0126
FMF is a rare disorder in Europe; 
however, it is no longer a rare 
disorder in populations such as 
Japan105. CAGS lists an incidence 
of 51–100 per 100,000 in Arab 
population; estimates of the incidence 
in specific eastern Mediterranean 
populations range from 1 in 2000 to 1 
in 100, depending on the population 
studied. Accordingly, MAF is seen 
marginally higher at 1.55%.
8.60/1.23
rs121908530
G > A
p.Gly156Arg
AGXT
Hyperoxaluria, primary, type i 
(PMIM: 259900).
Rare disorder
OMIM lists single gene.
Pathogenic 0/1/290 0.0017/./. ./.
rs118204113
G > A
p.Ala252Thr
HMBS
Porphyria, acute intermittent 
(PMIM:176000).
Rare form of porphyria.
OMIM lists single gene.
Pathogenic AD 0/1/289 0.0017/./0.0005 0./3.41
rs587776954
A > G
p.Met1Val; LoF
C12ORF57
Temtamy syndrome 
(PMIM:218340).
GARD lists this as a rare disorder.
OMIM lists single gene.
Pathogenic AR 0/2/288 0.0034/./0.0030 0./1.14
rs4149584
C > T
p.Arg121Gln
TNFRSF1A
Periodic fever, familial, autosomal 
dominant (PMIM:142680).
Rare disorder
OMIM lists single gene.
Pathogenic AR 0/4/287 0.0069/0.0069/0.0121 1.00/0.57
B.10 Risk Factor/association variants
B. 1. 1 Risk factors for supposedly rare disorders
rs61747728
C > T
p.Arg229Gln
NPHS2
Nephrotic syndrome, type 2, 
susceptibility to (PMIM: 600995). 
OMIM lists single gene. Rare 
disorder.
Risk factor
Rare disorder; however, Zaki et al.106 
concluded that the incidence of this disease 
seemed to be higher among Arab children 
(as seen in Kuwaiti hospitals over 5 years 
period) than in Western countries.
11–50 AR 0/8/281 0.0138/0.0146/0.0121 0.94/1.14
B. 2. 9 Risk factors/associations for common disorders
rs3135506
G > C
p.Ser19Trp
APOA5
Hypertriglyceridemia Familial, 
susceptibility to (PMIM: 145750). 
OMIM lists two genes. This is an 
inherited common disorder.
Risk factor for Common disorder AD 1/22/267 0.0412/0.0557/0.0706 0.74/0.58
rs2476601
G > A
p.Arg620Trp
PTPN22
Diabetes mellitus Type 1, insulin-
dependent, susceptibility to 
(PMIM:222100).
OMIM lists multiple genes. 
Complex disorder
And associated with susceptibility 
to Systemic lupus erythematosus as 
well (PMIM:152700).
Risk factor. Also risk factor for many other 
disorders such as SLE AR 0/5/280 0.0292/ 0.0274/0.0131 1.00/0.98
rs1799945
C > G
p.His63Asp
HFE
Hemochromatosis, type 1 - 
microvascular complications 
of diabetes, susceptibility to, 7, 
included (PMIM:235200). OMIM 
lists two genes. Common disorder.
Risk factor >100 AR 4/63/224 0.122/0.0731/0.1198 1.67/1.02
rs17158558
C > T
p.Arg982Cys
RET
Hirschsprung disease, 
susceptibility to, 1 (PMIM 142623).
OMIM lists single gene. Complex 
disorder.
Risk factor AD 0/15/273 0.0258/0.0220/0.0459 1.17/0.56
Continued
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variants is far from being complete26 and consideration of ethnic populations with consanguinity as in the GME 
study and our study can augment the list of human knock-out events.
We previously catalogued36 exome variants from 15 native Kuwaiti individuals of KWS subgroup (city- 
dwelling Saudi Arabian tribe ancestry24) and postulated that further samples were needed to capture the full 
spectrum of exome variability. The present study indicated that our previous work captured only a portion (22%) 
SNPs from Kuwaiti 
exomes seen annotated 
in OMIM against 
the CAGS disorder; 
Ref > risk alleles Disorder
ClinVar annotation for the disorder
(CAGS OMIM Id)
Incidence 
Rates Inheritance
Carrier 
Frequencies
(rr/rR/RR) RAF(KWT/1KGP/GME)
Ratios (KWT-
1KGP /KWT-
GME)
rs121918219
G > A
p.Arg274Gln
VANGL1
Neural tube defects, susceptibility 
to (PMIM: 182940). OMIM lists 
two genes.
The average incidence of NTDs 
is 1/1000 births, with a marked 
geographic variation107.
Risk factor. >100 AD 0/1/289 0.0017/./0.0010 ./1.71
rs1800858
G > A
p.Ala45Ala
Synonymous
RET
Hirschsprung disease, 
susceptibility to, 1; HSCR1 
(PMIM: 142623). CAGS reports 
an incidence rate of 1 per 5000 
live births.
OMIM lists single gene.
Risk factor AD 25/128/138 0.3058 /0.2464/0.2593 1.24/1.1793
rs1801131
T > G
p.Glu470Ala
MTHFR
Schizophrenia; sczd (PMIM: 
181500)
OMIM lists multiple genes. 
Complex trait.
Risk factor AD 31/128/132 0.3265/0.3264/0.3353 1.00/0.97
rs2282440
G > A
p.Thr329Ile
SDC3
Obesity (PMIM: 601665). OMIM 
lists multiple genes. Complex trait. Association AD 0/11/280 0.0189/0.0189/0.0282 1.00/0.67
rs77775126
C > T
p.Thr373Ile
RP1
Retinitis pigmentosa 1; RP1 
(PMIM: 180100). OMIM lists 
single gene. It is a common 
disorder. The disorder is seen 
in CAGS with prevalence as 
approximately 1/3,000 to 1/5,000.
Risk Factor by way of inference – since 
we associate “pathogenic” only with 
Mendelian disorder.
AR 0/11/280 0.0189/0.0189/0.0181 1.00/1.04
C. 6 Pathogenic variants that already appeared in the list of RARE & DELETERIOUS variants (see Table 3)
rs104893836
T > C
p.Gln106Arg
GNRHR
Hypogonadotropic 
hypogonadism 7 without anosmia 
(PMIM:146110). OMIM lists 
single gene. MEDSCAPE lists 
Hypogonadotropic hypogonadism 
as rare genetic disorder.
Pathogenic AR 0/1/290 0.0017/0.0012/0.0055 1.43/0.31
rs58331765
C > T
p.Val931Met
ABCA4
Stargardt disease 1 
(PMIM:248200). OMIM lists two 
genes.
Rare disorder.
Likely pathogenic/Pathogenic. AR 0/2/288 0.0034/0.0028/0.0005 1.23/6.82
rs61753185
G > A
p.Arg77Gln
TYR
Tyrosinase-negative 
oculocutaneous albinism, Type 
IA (PMIM:203100). OMIM lists 
single gene.
Rare disorder.
Pathogenic for Tyrosinase-negative 
oculocutaneous albinism AR 0/1/290 0.0017/0.0004/0.0005 4.30/3.41
rs61754375
G > A
p.Arg299His
TYR
Tyrosinase-negative 
oculocutaneous albinism, Type IA 
(PMIM: 203100).
OMIM lists single gene.
Rare disorder.
Pathogenic for Tyrosinase-negative 
oculocutaneous albinism AR 0/1/286 0.0017/0.0002/. 8.60/.
rs34424986
G > A
p.Arg275Trp
PARK2
Parkinson disease 2, autosomal 
recessive juvenile; PARK2 
(PMIM:600116). OMIM lists single 
gene. Rare disorders.
Pathogenic 0/2/289 0.0034/0.0034/. 1.00/.
rs56208331
G > A
p.Asp426Asn
GATA4
Tetralogy of fallot; 
(PMIM:187500).
OMIM lists single gene.
Rare disorder.
Pathogenic AD 0/2/289 0.0034/0.0034/0.0025 1.00/1.36
D. 2 risk factor variants that already appeared in Tables 3 and 6
rs121918530
A > G
p.Asn261Ser
MEF2A
Coronary artery disease/
myocardial infarction (PMIM: 
608320). OMIM lists single gene. 
However, it is a complex disorder.
Risk factor by way of inference AD 0/6/284 0.0103/0.0004/0.0020 25.82/5.12
rs11558538
C > T
p.Thr105Ile
HNMT
Asthma, susceptibility to (PMIM: 
600807). Common disorder 
OMIM lists multiple genes.
Risk factor AD 7/55/212 0.1186/0.0595/0.0968 1.99/1.23
Table 7. Arab disorders (annotated in CAGS) for which the OMIM-listed risk variants were seen in Kuwaiti 
exomes.
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of variability. The repertoire of ‘all’ SNVs and ‘population-specific’ variants increased with the number of samples 
sequenced and did not reach a plateau (Fig. 2). However, once population-specific variants were divided into 
personal and genuine polymorphic variants, the later reached a plateau. These data suggested that most of the 
Kuwaiti-specific polymorphisms within coding regions were restricted to approximately 10,000 positions (Fig. 2, 
dashed blue line).
Utility of whole-exome data in population structure analysis produces results congruent to those obtained 
using genome-wide genotype data54. In this study, principal component analysis of the merged data set of exome 
variants from Kuwait, 1KGP global populations, and Qatar confirmed the existence of three subgroups (Fig. 1) 
previously derived from genome-wide genotype data24 in Kuwaiti population. The KWB subgroup showed greater 
genetic affinity towards African populations, and the other two clearly demarcated subgroups (namely KWP and 
KWS) were between South Asian and European populations. Furthermore, the three substructures of the Qatari 
population25 lied akin to Kuwaitis. These results were supported by evidence from pFST likelihood ratio tests, 
which identified variants that differentiated the subgroups. The population-wide occurrence of Kuwaiti SAFD 
variants in the context of maximum allele frequency populations indicated pairing of Kuwaiti individuals mostly 
with Europeans and Ashkenazi Jewish populations from 1KGP phase 3 and gnomAD data sets. Such genetic 
relatedness among Middle Eastern, European and Ashkenazi Jewish populations was further confirmed through 
performing population genetic analyses (FST and PCA) by way of including genotype data from Ashkenazi Jews 
as well (Figs 4 and 5). Notably, in line with previous studies43, population genetic analysis presented in this study 
demonstrated the genetic relatedness among Middle Eastern, European and Ashkenazi Jewish populations.
The Kuwaiti exomes, presented in this study, included 46 clinically significant deleterious variants that are 
rare in global populations and in Kuwaiti exomes (except for three) (pathogenic: 35; drug response:1; risk factor: 
10). 28 of the 36 pathogenic variants followed AR mode of inheritance and the 7 of the 10 risk factor variants 
followed AD mode of inheritance. Disorders associated with 20 of the 46 variants were seen in Arab popula-
tions. Three of the 46 variants reached an MAF value characterizing low-frequency variants in Kuwaiti exomes; 
two of these three were risk factor and one was drug response variant; and the allele frequencies were com-
parable with GME data set (see Table 3)-(rs61742245-VKORC1:1.04%,1.37%; rs1800553-ABCA4:2.41%,2.1%; 
rs11909217-LIPI:1.72%,1.31%). The three variants indicating high risk ratios in Kuwaiti exomes for disease 
pathogenesis and response to medication were: the VKORC1 variant was associated with warfarin resistance 
(AD) (heterozygous in four individuals and homozygous recessive in one individual), the ABCA4 variant was 
associated with susceptibility to age-related macular degeneration (AD) (heterozygous in 12 individuals and 
homozygous recessive in one individual), and the LIPI variant was associated with susceptibility to hypertri-
glyceridemia (AD) (heterozygous in 10 individuals). Mendelian and rare genetic disorders as well as monogenic 
forms of common complex diseases are often associated with rare coding variants. The rare coding variants can 
have remarkably different allelic frequencies in different ethnic populations compared with the 1KGP popula-
tions10,55. The data presented above reported rare variants associated with not only rare Mendelian disorders but 
also with complex disorders. This observation is in agreement with literature reports on many examples of rare 
and low-frequency variants associated with complex phenotype traits and common disorders (a review of some 
of the relevant studies are as listed in Table 1 in Schork et al.56). An interesting example of rare & deleterious “risk 
factor” variants associated with increasing risk for complex disorders was the GHRL variant (rs34911341-C/T; 
Arg51gln) which OMIM associated with susceptibility to the complex disorder of obesity (along with genes such 
as POMC, SDC3 and ADRB2); the variant was originally seen in 6.13% of 96 unrelated Swedish female subjects of 
morbid obesity (BMI 42.3 ± 3.4 Kg/m2)57. The variant had been seen in GME data set and in one individual from 
our study cohort; incidentally, the individual was morbidly obese female with a BMI of 44.3 kg/m2; Though our 
study cohort consisted 48 morbidly obese female individuals, only one of them carried this GHRL allele.
The study identified in Kuwaiti exomes a set of 21 missense SNVs (that were predominantly ‘common’ in 
both Kuwaiti exomes and 1KGP populations as well as in GME) mapping to drug-binding domains and were of 
pharmacogenomic relevance (relating to complex disorders, such as sickle-cell anaemia, hypertension, diabetes, 
asthma, cancer and chemical dependence). 7 of these 21 variants were also observed as Arab mutations associ-
ated with complex disorders in Arab populations (Table 5). Of the 21 pharmacogenomic SNVs, the CYP2C8*3 
variants encoding two linked amino acid substitutions46 were particularly evident (Table 4) in Kuwaiti exomes; 
risk allele frequencies at these two variants were 12% in Kuwaiti exomes, 10.4% in GME and 4.6% in 1KGP; the 
risk alleles co-segregated in 33 individuals in our study cohort. CYP2C8 has emerged as a significant pharma-
cogene58,59 and is responsible for biotransformation of 5% of currently used drugs that undergo phase 1 hepatic 
metabolism60. The CYP2C8*3 variants regulate the dosage of the diabetes drugs rosiglitazone and repaglinide61,62. 
The minor alleles of the CYP2C8*3 variants were also associated with decreased metabolism of paclitaxel59. The 
ADRB2 variant (occurring with an MAF of 1.2% in Kuwaiti exomes, 1.6% in GME and 0.4% in 1KGP) regulates 
the efficacy of the asthma drug terbutaline and beta-blocking agents used to treat heart failure63. ADRB2 variant 
had also been correlated with the risk of type 2 diabetes, obesity and hypertension63; six individuals from our 
study cohort carried risk allele at this variant.
The identified 24 SAFD variants (all of which were missense variants – see Table 6) with clinical signifi-
cance included (a) two pathogenic variants (with AR mode of inheritance) associated with the rare disorders of 
Corticosterone methyloxidase type 2 deficiency and Carboxypeptidase N deficiency); (b) four drug response’ var-
iants associated with toxicity to the drugs of cisplatin or cyclophosphamide and with response to anti-coagulation 
drugs; (c) sixteen risk/protective’ variants associated with complex traits (ex. asthma, Parkinson’s disease, obesity, 
nephrolithiasis, melanoma 6, and alcohol dependency); and (d) two ‘Associated’ variants relating to traits of FPG 
levels and skin/hair/eye pigmentation. The gnomAD populations that showed highest MAFs at these 24 variants 
were Ashkenazi Jews (15 instances) and Europeans including Finnish (6 instances). The 1KGP populations that 
showed the highest MAFs were Europeans (14) and South Asians (7). As expected, a major number of these 
variants were ‘common’ (20 in Kuwaiti exomes and 14 in 1KGP data). The associated disorders are common in 
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dbSNP ID; Ref_risk 
alleles; gene
DISORDER; (PMIM); Number of OMIM-listed 
genes for the disorder; Reference for the Arab 
study.
Clin. Signific.; 
CAGS inciden. 
(per 100,000)
Inheritance mode
of the disorder
CARRIER
FREQ
(rr/rR/RR)
RAF
(KWT_RAF/1KGP_RAF/GME_RAF
RATIO
(KWT-1KGP/
KWT-GME)
A. 16 Instances wherein the identified functional variants match with the variants reported in arab studies.
4 Rare & deleterious variants – Pathogenic and rare disorder.
rs137853054 (G_A)
PARK2
Parkinson disease, juvenile, type 2; (PMIM:600116). 
GARD lists this as rare disorder. OMIM lists single 
gene92;
Pathogenic and rare 
disorder AR 0/2/288 0.0034/0.0002/0.0025 17/1.3503
rs61754375
(G_A)
TYR
Tyrosinase-negative oculocutaneous albinism, Type 
IA; (PMIM:203100) – OMIM lists single gene108;
Pathogenic and rare 
disorder AR 0/1/286 0.0017/0.0002/. 8.5/.
rs121964924 (A_G)
DPYS
Dihydropyrimidinase deficiency; (PMIM:222748) – 
OMIM lists single gene109;
Pathogenic and rare 
disorder AR 0/1/289 0.0017/0.0002/0.0020 8.5/0.8424
rs58331765 (C_T)
ABCA4
Stargardt disease 1; (PMIM:248200) – OMIM lists 
two genes93;
Pathogenic and rare 
disorder AR 0/2/288 0.0034/0.0028/0.0005 1.2143/6.7460
2 Safd variants
rs61757294 (A_G)
CYP11B2
Corticosterone methyloxidase type 2 deficiency. 
(PMIM: 610600)110. this cited study is on Iranian-
Jewish origin patients.
Pathogenic and rare 
disorder
DR; this and 
rs28931609 to be 
homozygous.
??
0.1519/0.0531/?
For variants of DR mode of inheritance 
higher MAF is alright though it is a 
pathogenic variant.
2.8606/?
rs1801280 (T_C) 
NAT2
Slow acetylator due to N-acetyltransferase enzyme 
variant; (PMIM:243400) – OMIM lists single 
gene111;
Drug Response AR 41/134/100 0.3927/0.2927/0.4340 1.3416/0.9047
8 Cags arab disorders
rs79204362 (C_T)
CYP1B1
Early onset of Glaucoma, digenic; (PMIM: 231300) 
– OMIM lists single gene112; This is a rare disorder 
but reaches high prevalence in Saudi Arabian 
populations.
Pathogenic and rare 
disorder; 11–50 AR 0/6/284
0.010/0.004/0.013
CTGA reports 1 in 2,500 among Saudi 
Arabians. MAF is only marginally higher 
at 1.03%.
2.4587/0.7553
rs61732874 (C_A)
MEFV
Familial Mediterranean Fever (FMF) Recessive; 
(PMIM: 249100) – OMIM lists single gene113;
Pathogenic; rare 
disorder 51–100 AR 0/9/278
0.015/0.001/0.012
FMF is a rare disorder in Europe; it is no 
longer rare in certain populations105. CAGS’ 
incidence is 51–100; varies 1/2000 to 1/100 
in eastern Mediterranean populations. Thus, 
MAF of 1.55% is acceptable for pathogenic 
variant.
8.6026/1.2281
rs121908530 (G_A)
AGXT
Type 1 primary Hyperoxaluria (PMIM: 259900) – 
OMIM lists single gene114;
Pathogenic; rare 
disorder ? 0/1/290 0.001718/./. ./.
rs587776954 (A_G)
C12orf57
Temtamy syndrome (PMIM:218340) – OMIM lists 
single gene115;
Pathogenic; rare 
disorder AR 0/2/288 0.003436/./0.003021 ./1.1374
rs61747728 (C_T)
NPHS2
Susceptibility to Nephrotic syndrome, type 2 
(PMIM: 600995) – OMIM lists single gene116;
Risk factor for rare 
disorder. 11–50 AR 0/8/281 0.01375/0.0145767/0.012085 0.9433/1.1377
rs1799945 (C_G)
HFE
Type 1 Hemochromatosis - microvascular 
complications of diabetes, susceptibility to, 
7, included (PMIM:235200). OMIM lists two 
genes117–119;
Risk factor for 
common disorder; 
>100
AR 4/63/224 0.122/0.073/0.119 1.6693/1.0180
rs1801131 (T_G)
MTHFR
Schizophrenia; sczd (PMIM:181500) – OMIM lists 
several genes120;
Risk Factor; 
complex disorder; 
>100
AD 31/128/132 0.3265/0.3264/0.3353 1.0001/0.9736
rs77775126 (C_T)
RP1
Retinitis pigmentosa 1 (PMIM: 180100) – OMIM 
lists single gene121,122.
Risk factor by 
inference for 
common disorder; 
11–50
AR 0/11/280 0.0189/0.0189/0.0181 0.9999/1.0426
2 Variants that came up during the examination for arab study variants
rs1801133 (G_A)
MTHFR Susceptibility to T2DM in Lebanese
123,124. Risk Factor; complex disorder AR 12/81/197 0.1810/0.2454/0.2557 0.7376/0.7077
rs1801131 (T_G)
MTHFR
Protective effect: T2DM in Israel Jews and South 
Indians123,125.
Risk Factor; 
complex disorder AD 31/128/132 0.3265/0.2494/0.3353 1.3091/0.9737
B. 7 Instances wherein the identified pharmacogenomic variants are implicated in arab disorders through arab studies. in all the instances, multiple genes are involved in the disorder.
rs1042713 (A_G)
ADRB2
PharmGKB: drug response to asthma. OMIM: 
susceptibility to asthma, nocturnal PMIM:600807). 
Arab study: susceptibility to early onset obesity and 
insulin resistance96,102.
Drug response; 
complex disorder AD 82/126/55
0.5513/0.5244/0.5645 A->G (Arg16Gly) is 
causative; hence the frequencies of the risk 
allele G rather than the minor allele are listed.
1.0513/0.98
rs1042714
ADRB2
PharmGKB: drug response to asthma. OMIM: 
susceptibility to obesity and to childhood asthma. 
PMIM: 601665. Arab study: for Coronary artery 
disease/myocardial infarction103,104.
Drug response; 
complex disorder AR 19/90/176 0.2246/0.2053/0.2412 1.094/0.9312
rs1805087 (A_G)
MTR
PharmGKB: drug response to Rheumatoid arthritis. 
OMIM: does not list. Arab study: for Autism – 
North Iran97.
Drug response; 
complex disorder GG is the risk factor. 23/105/162 0.2603/0.2183/0.2021 0.2603/0.2021
rs1042522 (G_C)
TP53
PharmGKB: drug response to stomach neoplasm. 
OMIM: smoking related accelerated decline in 
lung function PMIM:608852; Arab study: in 
susceptibility to Breast Cancer in Tunisia98.
Drug response; 
complex disorder ?? 57/140/90 0.4425/0.5429/. 0.815/.
Continued
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dbSNP ID; Ref_risk 
alleles; gene
DISORDER; (PMIM); Number of OMIM-listed 
genes for the disorder; Reference for the Arab 
study.
Clin. Signific.; 
CAGS inciden. 
(per 100,000)
Inheritance mode
of the disorder
CARRIER
FREQ
(rr/rR/RR)
RAF
(KWT_RAF/1KGP_RAF/GME_RAF
RATIO
(KWT-1KGP/
KWT-GME)
rs1800497 (G_A)
ANKK1
PharmGKB: drug response to Schizophrenia. 
OMIM: Taq1A polymorphism associated with 
neuropsychiatric disorders. Arab study: risk factor 
for Schizophrenia (PMIM:181500) in Egyptians99.
Drug response; 
complex disorder AD? 7/85/197 0.1713/0.3257/0.1908 0.5259/0.8975
rs1801058 (T_C)
GRK4
PharmGKB: drug response to Hypertension. OMIM: 
does not list. Arab study: risk factor for myocardial 
infarction among hypertensive subjects in Jordan100.
Drug response; 
complex disorder AD? 16/101/173 0.2293/0.3067/0.292 0.7476/0.7079
rs699 (A_G)
AGT
PharmGKB: drug response to Hypertension. 
OMIM: susceptibility to Essential hypertension 
(PMIM:145500). Arab study: Reduced life-span 
through genetic susceptibilities to Hypertension and 
Myocardial Infarction in UAE101.
Drug response; 
complex disorder Mu? 91/127/47 0.583/0.7051/0.5534 0.8268/1.0535
C. 12 Instances wherein the genetic basis for the disorder has not been reported in arab studies.
4 Rare & deleterious variants
rs28940872 (C_T)
ACADS
Scad deficiency (PMIM:606885). Single gene listed 
in OMIM.
Pathogenic; rare 
disorder; AR 0/1/289 0.0017/0.0002/0.0015 8.5/1.1251
rs28941785 (C_T)
CTH
Cystathioninuria (PMIM:219500). Single gene listed 
in OMIM.
Pathogenic; rare 
disorder; AR. 0/2/281 0.0035/0.0026/0.0065 1.3461/0.5347
rs28940885 (C_T)
GALE
Galactose Epimerase Deficiency (PMIM:230350). 
Single gene listed in OMIM.
Pathogenic; rare 
disorder; AR 0/1/290 0.0017/0.002/0.0025 0.85/0.6751
rs114817817 (C_T)
SRGAP1
Susceptibility to Thyroid cancer, nonmedullary 2, 
(PMIM:188470). OMIM lists three genes for this 
disorder.
Risk Factor; 
common disorder AD; (AR,AD,MF) 0/1/285 0.0017/0.0006/0.0070 2.8333/0.2415
1 Safd variants
rs6504649 (C_G)
THR801ARG
XYLT2
Pseudoxanthoma elasticum, modifier of severity. 
(PMIM:264800). OMIM lists three genes.
Risk Factor; 
common disorder AR 60/136/94 0.4414/0.251/0.3962 1.7586/1.1139
8 7 Cags arab variants
rs118204113 (G_A)
HMBS
Acute intermittent porphyria (PMIM:176000). 
Single gene listed in OMIM.
Pathogenic; rare 
disorder AD 0/1/289 0.001718/./0.000504 ./3.4087
rs4149584 (C_T)
TNFRSF1A
Familial periodic fever, autosomal dominant. 
(PMIM:142680). Single gene listed in OMIM.
Pathogenic; rare 
disorder; 51–100 AR 0/4/287 0.0069/0.0069/0.0121 1.0000/0.5687
rs56208331 (G_A)
GATA4
Tetralogy of fallot (PMIM:187500). Single gene 
listed in OMIM.
Pathogenic; rare 
disorder; 51–100 AD 0/2/289 0.0034/0.0034/0.0025 0.9998/1.3645
rs104893836
(T_C)
GNRHR
Hypogonadotropic hypogonadism 7 without 
anosmia. (PMIM:146110). Single gene listed in 
OMIM.
Pathogenic; rare 
disorder AR 0/1/290 0.0017/0.0012/0.0055 1.4167/0.3069
rs2476601 (A_G)
PTPN22
Susceptibility to T1DM (PMIM:222100). Also 
associated with susceptibility to Systemic lupus 
erythematosus (PMIM:152700). OMIM lists 
multiple genes.
Risk Factor; 
common disorder AR 0/5/280 0.0292/ 0.0274/0.0131 1.00/0.98
rs17158558 (C_T)
RET
Susceptibility to hirschsprung disease 1 (PMIM 
142623). Single gene listed in OMIM.
Risk Factor; 
common disorder AD 0/15/273 0.02577/0.0219649/0.045867 1.1732/0.5618
rs121918219
(G_A)
VANGL1
Susceptibility to neural tube defects. (PMIM: 
182940); OMIM lists 5 genes.
Risk Factor; 
common disorder; 
>100
AD 0/1/289 0.001718/./0.001007 ./1.7060
D. 10 Instances wherein different mutations from the same gene are seen in arab studies (generally seen in omim but not in our exomes).
7 Rare & deleterious variants
rs121908736 (G_A) 
ADA
Partial adenosine deaminase deficiency 
(PMIM:102700).
Arab studies: CAGS reports another mutation from 
the same gene p.Arg282 > Gln126.
Pathogenic; rare 
disorder
AR, SM. Compound 
heterozygosity 0/2/285 0.0035/0.0018/0.0005 1.9444/6.9444
rs61757582 (G_A)
DHCR7
Smith-Lemli-Opitz syndrome (PMIM:270400).
Arab studies: N287K (861 C > A); R352Q 
(1055 G > A) (rs121909768; seen in OMIM); and 
R352L (1055 G > T)127.
Pathogenic; rare 
disorder AR 0/1/284 0.0018/0.0002/. 9/.
rs61753185$ (G_A)
TYR
Tyrosinase-negative oculocutaneous albinism, Type 
IA (PMIM:203100). Arab studies: c.817 G > C/p.
W272C (rs62645902; not seen in OMIM)108,128.
Pathogenic; rare 
disorder AR 0/1/290 0.0017/0.0004/0.0005 4.25/3.3730
rs116100695 (G_A)
PKLR
Pyruvate kinase deficiency of red cells 
(PMIM:266200). Arab studies: 1058 C > T; 
Thr353Met (rs74315362 seen in OMIM)129.
Pathogenic; rare 
disorder AR 0/2/289 0.0034/0.0016/0.0096 2.125/0.3547
rs41295338 (G_T)
TGM1
AR congenital ichthyosis 1 (PMIM:242300). Arab 
studies: Compound heterozygosity for missense 
mutations (R141H- rs121918718, R142H-
rs121918719), (p.Tyr136Ter-rs1057517836), 
(p.Ser326Cysfs*8), and Leu362Arg130,131
Pathogenic; rare 
disorder AR 0/2/288 0.0034/0.0022/0.0060 1.5454/0.5627
rs121434513 (G_C)
PNKD alias MR1
Paroxysmal Nonkinesigenic Dyskinesia 1 (PMIM: 
118800). Arab studies: c.20 C > T; A7V rs121434512 
– seen in OMIM132.
Pathogenic; rare 
disorder AD 0/1/289 0.0017/0.0002/0.0005 8.5/3.3530
Continued
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the region - Cholestasis of pregnancy (associated with the ATP8B1 variant), the most common AD disorder in 
pregnant women, has an incidence rate of 0.8%–1.46% in South Asian populations64; Hereditary prostate cancer 
(associating with the two ELAC2 variants) is one of the most prevalent cancers in Kuwait65; The corticosterone 
methyloxidase type 2 deficiency (associating with the CYP11B2 variant) is more common in people of Iranian 
Jewish ancestry66; and Coronary artery disease (associating with the MEF2A variant) has an incidence rate of 
approximately 6% in the Saudi Arabian population67.
In addition, two other SNVs from our analysis for functional variants were seen associated with quantitative 
traits in GWA studies – an SAFD LoF variant rs2228015/CCR7 associated with the complex hematological trait of 
lymphocyte count in European-ancestry people68 and a missense variant (rare in 1KGP but common in Kuwaiti 
exomes) rs117135869/TTC38 associated with a novel complex metabolic quantitative trait loci (mQTLs) in a 
cohort from Middle Eastern population48. Further search for presence in Kuwaiti exomes of OMIM-listed causal 
variants relating to CAGS disorders led to a list of additional 17 variants (see Table 7); 7 of these variants were 
“pathogenic” and the remaining 10 were “risk factor” variants. The analysis identified a total of 25 CAGS disorders 
dbSNP ID; Ref_risk 
alleles; gene
DISORDER; (PMIM); Number of OMIM-listed 
genes for the disorder; Reference for the Arab 
study.
Clin. Signific.; 
CAGS inciden. 
(per 100,000)
Inheritance mode
of the disorder
CARRIER
FREQ
(rr/rR/RR)
RAF
(KWT_RAF/1KGP_RAF/GME_RAF
RATIO
(KWT-1KGP/
KWT-GME)
rs34424986 (G_A)
PARK2
Parkinson disease, juvenile, type 2. (PMIM:600116). 
Arab studies: exon 4 deletion and a 2-base AG 
deletion in exon 2 (101–102) from the same gene 
associated with the disorder133. Not seen in OMIM. 
This table reports another variant rs137853054 seen 
in Arab study and in Kuwaiti exomes133–135.
Pathogenic; rare 
disorder 11–50 AR 0/2/289 0.0034/0.0004/. 8.5/.
3 Cags arab disorders
rs12021720 (T_C)
DBT
Maple syrup urine disease, intermediate, type II 
(PMIM:248600). Arab studies: c.1281 + 1 G > T in 
one patient from UAE. Not seen in OMIM136.
Pathogenic; rare 
disorder AR 5/67/218
0.1347/0.1082/0.12
The variant is in compound heterozygosity 
with [rs121965001]46. Hence high MAF is 
acceptable.
0.97/0.98
rs1800858 (G_A)
RET
Susceptibility to Hirschsprung disease 1; HSCR1 
(PMIM: 142623). Arab studies: c.1852T > C 
Cys618Arg mutation rs76262710. Seen in OMIM 
(for neoplasia)137,138.
Risk Factor; 
common disorder; 
11–50
AD 25/128/138 0.3058/0.2464/0.2593 1.24/1.1793
rs121918530 (A_G)
MEF2A
Coronary artery disease/myocardial infarction 
(PMIM:600660). Arab studies: (rs1059759 G > C) 
in Saudi Arabian patients139.
Risk factor by 
inference for 
complex disorder.
AD 0/6/284 0.01031/0.000399361/0.002014 25.8162/5.119
E. 7 instances wherein the Arab studies report different mutation from different gene (but associated with the disorder in OMIM). These disorders involve multiple genes. In general, the different gene and 
the different mutations are seen in OMIM associated with the disorder. The Arab mutations are not seen in Kuwaiti exomes.
rs11909217 (C_T)
LIPI
RARE & 
DELETERIOUS
Susceptibility to Hypertriglyceridemia, Familial 
(PMIM: 145750). OMIM lists LIPI and APOA5 for 
the disorder. Arab study: 3′ UTR C > G variant from 
APOC3 (not seen in OMIM or our exomes)95. This is 
an inherited common disorder.
Risk factor by 
inference; common 
disorder.
AD 0/10/280 0.0172/0.006/0.01309 2.8667/1.3138
rs3135506 (G_C)
APOA5
CAGS VARIANT
Risk factor; 
Common disorder AD 1/22/267 0.04124/0.0557109/0.070565 0.7402/0.5844
rs28932472 (G_C)
POMC
RARE & 
DELETERIOUS
Obesity, early-onset, susceptibility to (PMIM: 
601665). OMIM lists several genes. Arab study: 
rs1042713: Arginine 16 Glycine (Arg16Gly) 
polymorphism in ADRB2 gene; which is associated 
with susceptibility to nocturnal asthma in 
OMIM and our study. rs1042713 A_G: (AA:55, 
AG:126, GG:82) & (MAF_KWT, 1KGP, GME: 
0.5513/0.5244/0.5645)102.
Risk Factor;
common disorder AR,AD,MF 0/1/287 0.0017/0.0024/0.0005 0.7083/3.3730
rs34911341 (C_T)
GHRL
RARE & 
DELETERIOUS
Risk Factor; 
common disorder AR,AD,MF 0/1/290 0.0017/0.0026/0.0035 0.6538/0.4823
rs2282440 (G_A)
SDC3
CAGS variant
Association variant; 
common disorder; 
>100
AD 0/11/280 0.0189/0.0189/0.0282 0.9999/0.6703
rs11558538 (C_T)
HNMT
SAFD variant
Susceptibility to Asthma (PMIM: 600807). OMIM 
lists several genes.
Arab studies: 786 T > C [rs2070744] from the 5’ 
flanking region of NOS3 (OMIM lists this variant 
but the variant is not seen in Kuwaiti exomes)140.
Risk Factor for 
common disorder AD 7/55/212 0.1259/0.0595/0.0968 2.1159/1.3009
rs1801483 (G_A)
GCGR
SAFD Variant
T2DM (PMIM: 125853).
Arab studies: Ala222Val (rs1801133 C > T AR/
AD) mutation from MTHFR gene in Lebanese 
patients with T2DM and nephropathy123,124. 
The rs1801133 is seen in Kuwaiti exomes 
(MAF:KWT/1KGP/GME = 0.1810/0.2454/0.2557; 
AA/AG/GG: 12/81/197). Another MTHFR variant 
Glu429Ala (rs1801131 T_G AR) in homozygous 
form has protective effect in Israeli Jews123 
and South Indians125. The rs1801131 variant is 
seen in Kuwaiti exomes (MAF: KWT/1KGP/
GME = 0.3265/0.2494/0.3353; GG/GT/TT: 
31/128/132).
Risk factor by way 
of inference AD 0/22/269 0.0378/0.0042/0.0311 9/1.2148
Table 8. Evaluation of the identified variants for observation as Arab mutations in Arab studies.
www.nature.com/scientificreports/
22SCiENTifiC REPORTS |         (2018) 8:16583  | DOI:10.1038/s41598-018-34815-8
for which the OMIM-listed causal variants were seen in Kuwaiti exomes; such a poor turnout of only 25 was prob-
ably due to the small size of the cohort.
Of the 112 variants of clinical significance discussed so far, as many as 44 were ‘common’ variants in Kuwaiti 
exomes. Very often these common variants were relating to complex disorders. In this study, we did not ourselves 
delineate the variants associated with complex disorders; we rather just examined whether and which of the func-
tional variants identified in our study were annotated in OMIM, ClinVar, PharmGKB, and literature as associated 
with complex (or rare) disorders. A question arose as to whether the study cohort of 291 exomes had enough 
power. Of the 112 variants, 27 variants (comprising 1 rare, 3 low-frequency and 23 common variants) were also 
seen in our in-house GWAS data set of larger sample size; the set of 27 variants comprised 11 pharmacogenomic, 
9 SAFD, 5 CAGS and the two MTHFR variants associated with susceptibility to T2DM (Table 9). The MAF at 
these variants were comparable among the Kuwaiti exomes, GWAS data, and the GME data set; the carrier distri-
butions were also comparable with one another among the Kuwaiti exomes and GWAS data set.
Finally, disorders relating to 52 of the identified variants were observed in Arab population. Inheritance 
modes associated with these 52 variants were: 28 autosomal recessive, 15 autosomal dominant, and 9 ambiguous. 
25 of these variants were relating to ‘rare’ and 27 were relating to complex disorders. This study (based on 291 
exomes) provided data on 23 known Arab mutations for 23 disorders seen in Arab populations, data on 12 puta-
tive mutations for 12 disorders observed but not yet characterized for genetic basis in Arab population, and data 
on 17 additional putative mutations for disorders characterized for genetic basis in Arab populations. This data is 
useful for testing in future case-control studies.
Capturing the extent of genetic variation in Middle East region is poorly represented in global studies. 
However, the Greater Middle Eastern (GME) Variome Consortium26 has recently made a notable effort to address 
this concern by way of capturing genetic variations from exomes of 1,111 unrelated and supposedly healthy indi-
viduals from Northwest and Northeast Africa, Turkish peninsula, Syrian desert, Arabian Peninsula and Persia & 
Pakistan. The GME data set included 214 exomes from Arabian Peninsula (AP), of which 45 are from Kuwaiti 
population. Our study consisting of 291 Kuwaiti samples, sourced from the 3 Kuwaiti population subgroups, 
complements and augments the GME genetic variation data by way of presenting a higher number of exomes rep-
resenting a single state of AP namely Kuwait. It is further the case that the GME study discovered and presented 
the variegated genetic architecture in GME populations; this is complemented by the population genetics results 
from our study from a relatively larger sample set of native Arabs living in a single state from the Peninsula. The 
GME study demonstrated the utility of the GME exome data set in discovering the genetic basis of Mendelian 
disorders in Greater Middle Eastern populations; our study provides data on Arab mutations for 23 disorders and 
points to 31 OMIM-listed variants relating to disorders seen in Arab populations for testing in future case-control 
studies.
A potential limitation of this study arises from the number of exomes sequenced. Though the number of 
population-specific variants seemed to saturate with 291 exomes, the total number of “all” identified variants 
did not saturate (Fig. 2); this indicates that we need to sequence furthermore samples to sufficiently represent 
the Arab population from Kuwait. It is further the case that variants associated with only a small set of disorders 
observed in the region were seen in the reported Kuwaiti exome data.
In conclusion, the presented assessment of 291 exomes of unrelated healthy individuals unveiled the preva-
lence of rare as well as common variants related to various Mendelian disorders and common complex diseases 
that are predominantly inherited as recessive. The inclusion of different genome data sets in our analyses high-
lighted similarities in allele frequencies among Arabs and Jews, and among nomadic Bedouins and Africans. 
Furthermore, our data corroborates the Kuwaiti population substructures previously determined by genome-wide 
genotype data; the results on population structures from Kuwait is generally in agreement with the variegated 
genetic architecture seen in Greater Middle Eastern populations26. The striking occurrence of pharmacogenomic 
variants relating to common complex disorders, underlines the importance and need for cataloguing genetic 
variants in similar Arab populations of the Middle East region. This study is a significant addition to regional data 
resources (such as GME26) and global resources (such as 1kGP3,4) on human exome variability; however, a wide 
range of similar studies in the region are warranted to support genomic discoveries in medical and population 
genetics at the regional and global levels26.
Methods
Ethics Statement. The protocols used in the study were approved by the International Scientific Advisory 
Board and the Ethical Review Committee at Dasman Diabetes Institute, Kuwait. Written informed consent was 
obtained from participants before collecting blood samples. Identities of the participants were protected from 
public exposure, and samples/data were processed anonymously. All methods were performed in accordance with 
the relevant guidelines and regulations.
Selection of subjects for whole-exome sequencing. To capture the extent of exome variation in the 
entire Kuwaiti population, 291 healthy, unrelated native Kuwaiti individuals from the study cohorts used in our 
earlier studies were selected24,36,69,70. At the time of recruitment, all participants in this study were healthy and 
deemed free of Mendelian or rare genetic disorders, cognition or physical disability, mental retardation or chronic 
disorders, such as cancer. Distribution of the selected participants in three subgroups of Kuwaiti population24 was 
as follows: 109 in KWS (Saudi Arabian tribe ancestry), 126 in KWP (Persian ancestry) and 34 in KWB (nomadic 
Bedouin ancestry).
Whole-exome sequencing. High-quality DNA samples were enriched for exomes using TruSeq Exome 
Enrichment kit and the Nextera Rapid Capture Exome kit (Illumina Inc. USA). The captured libraries were then 
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dbSNP ID; Ref_
risk; gene
Type of variant & whether the 
variant has been observed in 
Arab studies Associated disorder
Risk allele frequency in 
Kuwaiti exomes/GME & 
Carrier distribution in 
Kuwaiti exomes
Risk allele frequency in 
Kuwaiti GWAS data set 
& Carrier distribution in 
GWAS data
rs699 (A_G) Pharmacogenomic variant for hypertension;
PharmGKB listed this variant as drug response 
for Hypertension). (OMIM lists this variant 
as susceptibility to Essential hypertension 
(PMIM:145500). Arab study implicates this in 
Reduced life-span through genetic susceptibilities 
to both Essential Hypertension and Myocardial 
Infarction in UAE101.
0.583/0.5534 0.5658
AGT Arab mutation 91/127/47 439/653/260
rs1805087 (A_G) Pharmacogenomic variant for Rheumatoid arthritis. Arab study implicates this in Autism – North Iran
97. 0.2603/0.2021 0.2262
MTR Arab variant. 23/105/162 77/456/819
rs1367117 (G_A) Pharmacogenomic variant for hypertension Hypertension 0.1448/0.1727 0.1647
APOB 5/74/211 33/379/939
rs2960306 (G_T) Pharmacogenomic variant for hypertension. Hypertension 0.371/0.362 0.3607
GRK4 42/129/166 182/612/559
rs1024323 (C_T) Pharmacogenomic variant for hypertension Hypertension 0.3718/0.3887 0.3544
GRK4 33/137/103 172/608/562
rs1801058 (T_C) Pharmacogenomic variant for hypertension
Arab study implicates this as risk factor for 
myocardial infarction among hypertensive subjects 
in Jordan100. PharmGKB listed this variant as drug 
response for Hypertension). (OMIM does not list 
this variant).
0.229/0.292 0.262791/529/733
GRK4 Arab mutation 16/101/173 .
rs1042713 (A_G) Pharmacogenomics variant for asthma.
Susceptibility to early onset obesity, insulin resistance 
etc.) in Saudi Arabia102. 0.5513/0.5645 0.5814
ADRB2 Arab mutation OMIM listed this variant for susceptibility to asthma, nocturnal PMIM:600807). 82/126/55 376/533/196
rs1800888 (C_T) Pharmacogenomics variant Drug response for asthma and heart failure 0.01211/0.0156 0.014
ADRB2 0/7/282 2/33/1316
rs10509681 (T_C) Pharmacogenomics variant for diabetes and cancer. Drug response for Rosiglitazone and Repaglinide 0.1197/1047 0.1223
CYP2C8 3/63/222 32/266/1053
rs1048943 (T_C) Pharmacogenomics variant. Warfarin sensitivity 0.065/0.0619 0.042
CYP1A1 3/32/256 4/101/1216
rs1042522 (G_C) Pharmacogenomics variant. Drug response for stomach neoplasm. 0.443/. 0.4039
TP53 Arab variant Susceptibility to Breast Cancer in Tunisia98 57/140/90 236/620/496
rs861539 (G_A) SAFD variant Cutaneous malignant melanoma 6, susceptibility to 0.3864/0.3836 0.3843
XRCC3 AD PMIM: 613972 35/151/100 166/517/422
rs35264875 (A_T) SAFD variant Skin/hair/eye pigmentation, variation in, SHEP10 0.1832/0.1677 0.1906
TPCN2 Association by GWAS PMIM: 612267; 12/72/178 59/397/895
rs1260326 (C_T) SAFD variant FPG quantitative trait locus 5 0.3945/0.5388 0.469
GCKR PMIM: 613463 47/134/108 312/645/396
rs7076156 (G_A) SAFD variant Uric acid nephrolithiasis, susceptibility to; 0.3351/0.28 0.3045
ZNF365 PMIM: 605990 33/129/129 130/562/659
rs5030737 (G_A) SAFD variant Mannose-binding protein deficiency. Complex trait 0.0790/0.0535 0.0673
MBL2 AD PMIM: 614372 2/39/231 6/167/1177
rs6232 (T_C) SAFD variant. Obesity, susceptibility to, Body mass index quantitative trait locus 12 0.0594/0.0524 0.046
PCSK1 PMIM: 612362 1/32/253 2/119/1227
rs1801280 (T_C) SAFD variant
Slow acetylator due to N-acetyltransferase enzyme 
variant. Toxicity to the drugs of cisplatin or 
cyclophosphamide.
0.3927/0.434 0.433
NAT2 PMIM: 243400 41/134/100 182/483/313
AR Arab mutation.
rs4792311 (G_A) SAFD variant Prostate cancer, hereditary, 2′;Complex trait 0.3552/0.3092 0.3396
ELAC2 PMIM: 614731 30/146/114 167/583/602
AR or AD?
Continued
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clustered using TruSeq Paired Cluster Kit V3 (Illumina Inc. USA) and sequenced in HiSeq 2000 using Illumina’s 
Sequence by Synthesis technology as 100 paired-end reads.
Exome data analysis. The HugeSeq71 computational pipeline was used to automate the variant discovery 
process. Sequence reads were aligned to the reference human genome build hg19 using BWA72. Prior to variant 
calling, alignment files were processed using the Genome Analysis Toolkit (GATK)73. Post-alignment procedures 
included PCR duplicate removal, local realignment around known indels and base quality recalibration. Best 
practices for the GATK workflow were followed, and standard hard filtering parameters74,75 were used for variant 
discovery from the processed alignment files. Variant calling on each sample’s BAM file was performed using 
HaplotypeCaller followed by joint genotyping analysis of the resultant gVCFs to create raw SNV and indel VCFs. 
Variants called in the sequenced exomes were restricted to intervals covered by both TruSeq (163 samples) and 
Nextera (128 samples) Exome Enrichment kits. To improve the quality of the data set, the resulting variant call 
sets were filtered by setting sample variant thresholds at ≥10X depth, <180X depth and genotype quality of >20. 
Variants with allele balance of <30% were removed to filter out sites where the fraction of non-reference reads 
was too low. Hardy–Weinberg Equilibrium was assessed using an exact test, as defined by Wigginton et al.76, and 
excluded sites with p-values of <10−5. Lastly, all variants with a call rate of <90% were excluded. Thus, after the 
variant quality filtering steps, only the consensus of variants determined using both kits appeared in the final 
VCFs.
Classifying the variants. The Ensembl genome database build 75 was used as reference for gene annotation. 
SNP Variation Suite (SVS) v8.7.1 from Golden Helix Inc77 was used to derive functional classifications of the 
identified variants. The identified SNVs and indels were categorised as ‘known’ and ‘novel’ based on the content of 
the single-nucleotide polymorphism database of dbSNP14678. Variants already reported in dbSNP146 were anno-
tated as ‘known’, and the others were annotated as ‘novel’. Variants observed in only a single exome from the study 
cohort and not seen in 1KGP or GME data sets were annotated as ‘personal’. Variants (excluding the ‘personal’) 
that were not observed in 1KGP phase 3 data were annotated as ‘population-specific’, and population-specific 
variants observed in more than one exome from the study cohort were annotated as ‘population-specific poly-
morphic’ variants. Variants leading to stop gain, stop loss, frameshift and damage in splice sites were annotated 
to cause LoF (loss of function). Variants were classified as ‘rare’ if MAF was <1% (personal variants were not 
considered as rare), as ‘low-frequency’ if MAF was 1–5% and as ‘common’ if MAF was ≥5%.
Principal component analysis of the merged set of exome variants from Kuwaiti and global 
populations. The 1KGP phase 3 exomes of 2,504 individuals from 26 populations, covering the four conti-
nents of Asia, Africa, America and Europe and 100 exomes of Qatari individuals44 were considered along with 
Kuwaiti exomes. An LD-pruned (LD threshold of 0.5) data set of 20,215 variants (having MAF of ≥5%) observed 
dbSNP ID; Ref_
risk; gene
Type of variant & whether the 
variant has been observed in 
Arab studies Associated disorder
Risk allele frequency in 
Kuwaiti exomes/GME & 
Carrier distribution in 
Kuwaiti exomes
Risk allele frequency in 
Kuwaiti GWAS data set 
& Carrier distribution in 
GWAS data
Has to be in compound 
heterogeneity with rs5030739
rs2108622 (C_T) SAFD variant – drug response. Acenocoumarin response – Dosage. Warfarin sensitivity PMIM: 122700 0.4102/0.3983 0.4146
CYP4F2 53/127/104 239/643/469
rs1801131 (T_G) CAGS; Arab mutation Schizophrenia; sczd. (PMIM:181500). OMIM lists several genes. 0.3265/0.3353 0.3527
MTHFR 31/128/132 146/659/544
rs4149584 (C_T) CAGS variant Periodic fever, familial, autosomal dominant. (PMIM:142680). 0.0069/0.0121 0.0113
TNFRSF1A
Genetics basis for the disorder 
has not been reported in Arab 
studies. AR
0/4/287 0/13/606
rs2282440 (G_A)
SDC3
CAGS variant
AD
Obesity, early-onset, susceptibility to (PMIM: 
601665).
0.0189/0.0282
0/11/280
0.0147
0/11/361
rs17158558 (C_T) CAGS variant
Hirschsprung disease, susceptibility to, 1 (PMIM 
142623). Complex disorder. Genetics basis is not 
reported in Arab studies.
0.0260/0.0459 0.0325
RET AD 0/15/273 2/84/1266
rs1799945 (C_G) CAGS variant
Hemochromatosis, type 1 -microvascular 
complications of diabetes, susceptibility to, 7, 
included. (PMIM:235200). It is a common disorder.
0.1219/0.1198 0.1156
HFE AR 4/63/224 23/264/1061
rs1801133 (G_A)
MTHFR
AR
Arab mutation Susceptibility to T2DM in Lebanese
123,124 0.1810/0.2557
12/81/197
0.255
511/89/751
rs1801131 (T_G)
MTHFR
AD
Arab mutation
Protective effect T2DM in Israel Jews123 and
in South Indians.
0.3265/0.3353
31/128/132
0.3527
147/660/546
Table 9. Comparison of allele frequencies & carrier distribution of the reported variants from Kuwaiti exome 
data set with a larger data set of our in-house genome-wide genotype data.
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in all three Kuwaiti subgroups and the regional and global populations was created. Golden Helix SVS software 
v8.7.1 was used to perform principal component analysis with the merged data set.
pFST likelihood ratio tests: Comparison of allele frequency distribution among the Kuwaiti 
population subgroups. Reference alleles and alternate alleles were binned to set the standard for ‘Kuwaiti 
exome’. In order to detect alleles driving differentiation among the three Kuwaiti subpopulation groups of KWP, 
KWS and KWB, pFST likelihood ratio tests79 for allele frequency differences in autosomal variants (filtered for 
missingness rate and deviation from Hardy–Weinberg equilibrium) were performed.
Identification of SNVs with significant differences (SAFD variants) in allele frequencies between 
Kuwaiti and global populations. Autosomal SNVs observed in both Kuwaiti exomes and 1KGP phase 3 
exomes4 were identified, and SNVs for which minor alleles were not observed in Kuwaiti exomes were excluded. 
SAFD variants that exhibited significant allele frequency differences were identified by performing one-sided 
binomial exact tests (allele frequencies in 1KGP global populations were considered as ‘expected’), followed by 
Bonferroni correction. A p-value threshold of 0.05 was used to assess the significance of allele frequency differ-
ences. ClinVar80 data resource was used to assess the clinical significance of the identified SAFD variants. In the 
context of population structure analyses, populations from gnomAD data set8 were also used to compare allele 
frequency distributions. The comprehensive scrutinization of population-wide occurrence was performed by 
considering the paired incidence of populations with maximum allele frequency.
Principal Component Analysis of the merged set of Kuwaiti exomes, Ashkenazi Jews, 1KGP 
phase 3 and Qatar and FST analysis. We combined Kuwaiti exomes with the data sets from Ashkenazi 
Jews43, 1KGP phase 34 and Qatar44. The combined data set of coding-region variants was cleaned and LD-pruned 
to obtain a total of about 896 variants and 3,336 individuals representing world populations. Principal com-
ponent analysis (PCA) was performed using smartpca in the EIGENSOFT software package (v 6.1.4)81,82. 
Two-dimensional and three-dimensional scattered PCA plots were created using RStudio83 (v 1.1.423). Mean 
pairwise FST values and the matrix between populations were generated using PLINK84 (v 1.9). The FST heatmap 
was created using RStudio (v 1.1.423).
Examining OMIM and ClinVar annotations for inferring clinical significance of SNVs. OMIM 
and ClinVar should mention the Kuwaiti exome SNV, with literature evidence and citation reference, as an asso-
ciated variant for a disorder; the dbSNP identifier of the SNV and the observed risk allele should be mentioned 
as such in the OMIM and ClinVar annotation80,85. The clinical significance for the variant should be mentioned 
consistently with the same term (such as ‘pathogenic’ or ‘risk factor’ or ‘protective’ or ‘drug response’) in all the 
records for the disorder; it should not be the case that few records list the significance as ‘pathogenic’ and few 
other records list as ‘benign’ or ‘conflicting interpretation’ for the disorder; ClinVar records listing “not specified” 
for the data item of ‘conditions’ were not considered. As is the practice86, in cases of ClinVar variants with con-
flicting annotation for clinical significance, evidence from a peer-reviewed publication and manually curation 
(OMIM) takes precedence over evidence from clinical testing submissions. ClinVar defines “Pathogenic” variants 
as those that are interpreted for Mendelian disorders; or as those that have low penetrance; “Drug response” 
variants as those that affect drug response, and not a disease; “Risk factor” variants as those that are interpreted 
not to cause a disorder but to increase the risk; “Association” variants as those that were identified in a GWAS 
study and further interpreted for their clinical significance; “Protective” variants that decrease the risk of a dis-
order, including infections; and “Susceptibility to” variants that increase the risk of a disorder. In those instances, 
wherein ClinVar annotated a variant as “pathogenic” but the associated disorder was “complex or common or 
more prevalent in the study population” or the patient carrying the variant was annotated in OMIM as suscepti-
ble to the disorder (which is often a common disorder), we reannotated the variant as “Risk factor by inference”.
Classifying disorders as ‘rare’ or ‘complex’. Various resources that were examined to ascertain whether 
the disorder is rare or common: Catalogue of Transmission Genetics in Arabs (available at http://cags.org.ae/
ctga/), Genetic and Rare Disease (GARD) Information Centre (available at https://rarediseases.info.nih.gov/dis-
eases/), Genetics Home Reference (available at https://ghr.nlm.nih.gov/), Medscape (available at https://gene-
aware.clinical.bcm.edu/GeneAware/AboutGeneAware/DiseaseSearch.aspx) and literature.
Examining the Kuwaiti exomes for rare, deleterious and pathogenic variants. ‘Known’ mis-
sense and LoF SNVs having MAF of <1% in the 1KGP phase 3 data4 and ExAC database8 were catalogued. 
Of these, only the variants annotated as damaging by both SIFT87 and PolyPhen-288 tools were retained. The 
Kuwaiti exomes were examined for such variants. As an additional step, the resulting variants were filtered based 
on their Combined Annotation-Dependent Depletion score89 to prioritise functional, deleterious and patho-
genic variants across many functional categories, effect sizes and genetic architectures. A scaled score of ≥20 was 
applied to retrieve only those variants that were predicted to be among the top 1% of deleterious variants in the 
human genome. The above set of variants were screened for clinical significance using the OMIM85 and ClinVar80 
databases.
Variants found to be ‘rare’ within global populations but ‘common’ within Kuwaiti popula-
tion. A data set of SNVs that are rare in 1KGP phase 3 populations but common within Kuwaiti exomes was 
created. For such missense variants, scores predicting their pathogenicity were calculating using the REVEL90 
software.
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Examining the pharmacogenomic relevance of Kuwaiti exome variants. Variants of pharmacog-
enomic relevance were delineated using the resources built upon the concept of druggable genome originally 
formulated by Hopkins and Groom49 and PharmGKB50. From the data set of variants derived for Kuwaiti exomes, 
missense SNVs (with MAF of >1%) that are not deleterious (i.e. SIFT and PolyPhen-2 scores were outside the 
deleteriousness range) were mapped to protein domains (using InterPro91) and checked for inclusion in the list 
of 130 domains reported by Hopkins and Groom. From the resulting set of variants mapping to drug-binding 
domains, only those for which pharmacogenomic annotation was available in PharmGKB database were retained.
Data Availability
The 291 individual VCF files were combined to include a genotype (ref/ref, ref/alt, /alt/alt) for each exome. The 
resulting VCF file containing genotypes for the final variant set of 173,849 SNVs and indels is available online at 
ftp://dgr.dasmaninstitute.org.
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